var title_f31_42_32416="Rigi Scan nocturnal erections";
var content_f31_42_32416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Rigi-Scan recording to quantify nocturnal erections",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A normal scan (above) records an adequate number, tumescence, and rigidity of nocturnal erections compared to an abnormal scan (below).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32416=[""].join("\n");
var outline_f31_42_32416=null;
var title_f31_42_32417="Treatment protocols for pancreatic cancer";
var content_f31_42_32417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for pancreatic cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32417/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32417/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32417/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32417/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32417/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32417/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32417/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32417/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/42/32417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8525276\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with pancreatic cancer, both in the adjuvant setting and for advanced disease.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with pancreatic cancer. Additional regimens may be added over time, particularly as treatment for pancreatic cancer evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with pancreatic cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"       \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link\">",
"       \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link\">",
"       \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8525441\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8525449\">",
"    <span class=\"h2\">",
"     Adjuvant setting",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8525474\">",
"    <span class=\"h3\">",
"     Adjuvant gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef81436 \" href=\"mobipreview.htm?26/2/26669\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8525513\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8525538\">",
"    <span class=\"h3\">",
"     Gemcitabine monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef60330 \" href=\"mobipreview.htm?35/56/36749\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8525617\">",
"    <span class=\"h3\">",
"     FOLFIRINOX (fluorouracil plus leucovorin, irinotecan, and oxaliplatin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79571 \" href=\"mobipreview.htm?43/3/44094\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936511973\">",
"    <span class=\"h3\">",
"     Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 4",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85690 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32417=[""].join("\n");
var outline_f31_42_32417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8525276\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8525441\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8525449\">",
"      Adjuvant setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8525474\">",
"      - Adjuvant gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8525513\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8525538\">",
"      - Gemcitabine monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8525617\">",
"      - FOLFIRINOX (fluorouracil plus leucovorin, irinotecan, and oxaliplatin)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H936511973\">",
"      - Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/2/26669\" title=\"table 1\">",
"      Gemcitabine for nonmetastatic pancreatic and biliary cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/56/36749\" title=\"table 2\">",
"      Gemcitabine for metastatic pancreatic and biliary tract cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/3/44094\" title=\"table 3\">",
"      FOLFIRINOX for metastatic pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 4\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=related_link\">",
"      Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=related_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=related_link\">",
"      Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_42_32418="Emergent evaluation of pediatric headache";
var content_f31_42_32418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65204%7EEM%2F58858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65204%7EEM%2F58858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Headache in child with no immunocompromise, no shunt, and no known trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 527px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CSF: cerebrospinal fluid; BP: blood pressure.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Headache in child with focal neurologic examination or papilledema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 544px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; CSF: cerebrospinal fluid; RBCs: red blood cells; WBCs: white blood cells.",
"     <br>",
"      * Distinguish idiopathic intracranial hypertension from cerebral venous thrombosis by obtaining magnetic resonance imaging or magnetic resonance venogram.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32418=[""].join("\n");
var outline_f31_42_32418=null;
var title_f31_42_32419="Cycloserine: Pediatric drug information";
var content_f31_42_32419=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cycloserine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"    see \"Cycloserine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/49/14100?source=see_link\">",
"    see \"Cycloserine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13264878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Seromycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitubercular Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"      see \"Cycloserine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tuberculosis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 10-20 mg/kg/day divided every 12 hours up to 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Initial: 250 mg every 12 hours for 14 days, then give 500 mg to 1 g/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Urinary tract infection: Adults: 250 mg every 12 hours for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 36-48 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Seromycin&reg;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment in pulmonary or extrapulmonary tuberculosis; treatment of acute urinary tract infections caused by",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Enterobacter",
"     </i>",
"     species when less toxic conventional therapy has failed or is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F155586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CycloSERINE may be confused with cyclobenzaprine, cycloSPORINE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F155584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrhythmia, heart failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Coma, confusion, dizziness, drowsiness, headache, paresis, psychosis, restlessness, seizures, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Folate deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dysarthria, hyperreflexia, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic manifestations",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cycloserine or any component; epilepsy, depression, severe anxiety or psychosis, severe renal insufficiency, chronic alcoholism",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage must be adjusted in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the neurotoxic effect of CycloSERINE. Specifically, the risk for seizures may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethionamide: May enhance the adverse/toxic effect of CycloSERINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of CycloSERINE. Specifically, CNS toxicity may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1046719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May increase vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and folic acid dietary requirements",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13494780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. Cycloserine crosses the placenta and can be detected in the fetal blood and amniotic fluid. The American Thoracic Society recommends use in pregnant women only if there are no alternatives (CDC, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal, hepatic, hematological tests, and plasma cycloserine concentrations",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1046713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjust dosage to maintain blood cycloserine concentrations &lt;30 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by competing with amino acid (D-alanine) for incorporation into the bacterial cell wall",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &sim;70% to 90% from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; appears in breast milk, bile, sputum, synovial fluid and CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Not plasma protein bound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Patients with normal renal function: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 60% to 70% of an oral dose excreted unchanged in urine by glomerular filtration within 72 hours, small amounts excreted in feces, remainder is metabolized",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/49/14100?source=see_link\">",
"      see \"Cycloserine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; avoid alcohol. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/42/32419/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13192 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32419=[""].join("\n");
var outline_f31_42_32419=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13264878\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046711\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046704\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155538\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155524\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046715\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046714\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155586\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155584\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046718\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046703\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299109\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155533\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046719\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155534\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494780\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046710\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046713\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046702\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046717\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046708\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13192\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13192|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=related_link\">",
"      Cycloserine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/49/14100?source=related_link\">",
"      Cycloserine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_42_32420="Pericardial effusion four chamber echocardiogram";
var content_f31_42_32420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/66715/4chperef_conv.mp4?title=Pericardial+effusion+four+chamber+echocardiogram\" style=\"width:360px;height:272px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical 4 chamber view from a 2-D echocardiogram shows a large pericardial effusion surrounding the heart. The heart has a swinging motion during the cardiac cycle and there is slight compression of the right atrium early in diastole, suggesting early tamponade.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32420=[""].join("\n");
var outline_f31_42_32420=null;
var title_f31_42_32421="NSIP CXR and HRCT";
var content_f31_42_32421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nonspecific interstitial pneumonitis (NSIP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 566px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Frontal and lateral chest radiographs in a 7-year-old child with NSIP (A, B) show subtle ground glass abnormality in the upper lungs, with a marked pectus excavatum. High resolution computed tomography (HRCT) scans (C, D) at two levels show patchy ground glass abnormality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Epstein, MD and Leland L Fan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32421=[""].join("\n");
var outline_f31_42_32421=null;
var title_f31_42_32422="M mode tricuspid valve";
var content_f31_42_32422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55489%7ECARD%2F65162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55489%7ECARD%2F65162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardogram of tricuspid valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transducer is at the left parasternal area and two of the tricuspid valve leaflets are seen. The movement of the valves is similar to that of the mitral valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) and M mode images showing a normal tricuspid valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tricuspid valve (tv) can be imaged from the precordial long axis view (panel A). In panel B, the M-mode beam is directed through the septal leaflet (inset); an M-mode echocardiogram typically shows a single anteriorly moving leaflet. In this example, atrial fibrillation is present, resulting in a wave form that is of irregular duration, shows early diastolic opening, and occasional small movements arising from rapid fibrillatory contraction. Additionally, the right atrium (RA) is enlarged.",
"    <div class=\"footnotes\">",
"     RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32422=[""].join("\n");
var outline_f31_42_32422=null;
var title_f31_42_32423="Filling patterns Doppler echo";
var content_f31_42_32423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular diastolic dysfunction is a predictor of outcome after a myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulsed Doppler recordings of transmitral filling (panel A) and color M-mode Doppler echocardiography (panel B) are methods for evaluating left ventricular (LV) diastolic function. In a normal filling pattern, the mitral E-wave deceleration time (DT) is 140 to 240 ms and the M-mode flow propagation velocity (Vp) is &ge;45 cm/s). In diastolic dysfunction with impaired relaxation the DT is prolonged &ge; 240 ms and Vp is normal or reduced (&lt;45 cm/s). In a pseudonormal filling pattern the DT may be normal or prolonged, but the Vp is &lt;45 cm/s. In diastolic dysfunction with a restrictive filling, the DT is &lt;140 ms and the Vp is normal or &lt;45 cm/s. Patients with a myocardial infarction who have a restrictive or pseudonormal pattern have an increased incidence of left ventricular dilation and cardiac death.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Moller JE, Sondergaard E, Poulsen SH, Egstrup K. J Am Coll Cardiol 2000; 36:1841. Reprinted with permission from the American College of Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32423=[""].join("\n");
var outline_f31_42_32423=null;
var title_f31_42_32424="Drug resistance testing in the clinical management of HIV infection";
var content_f31_42_32424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug resistance testing in the clinical management of HIV infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32424/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32424/contributors\">",
"     Michael J Kozal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32424/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32424/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32424/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32424/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/42/32424/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and transmission of HIV variants resistant to antiretroviral drugs continues to limit the efficacy of treatments for HIV infection. Factors influencing the development of HIV drug resistance and the role of genotypic and phenotypic testing in different clinical scenarios will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative advantages and disadvantages of the tests and clinical trial data supporting their use, an introduction to the understanding of resistance mutations, and the issue of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    resistance related to prevention of mother-to-child HIV transmission are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/46/3814?source=see_link\">",
"     \"Clinical trials of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONTRIBUTING FACTORS TO RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors influence the development of HIV drug resistance, including the biology of HIV, genetic barriers to resistance, regimen potency, pharmacokinetics of antiretroviral drugs, and medication adherence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     HIV biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection is characterized by high rates of replication, with more than 10(9) virions produced daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, HIV reverse transcriptase, which is responsible for replicating the viral genome, is error-prone. The combination of high rates of replication and frequent introduction of mutations during each round of replication leads to the frequent occurrence of randomly generated mutations, some of which confer drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/3\">",
"     3",
"    </a>",
"    ]. The resulting population of genetically related, but distinct, HIV variants in a patient is referred to as a \"quasispecies.\"",
"   </p>",
"   <p>",
"    Some drug-resistant variants, which replicate less efficiently than drug-sensitive strains in the absence of drug, are thought to preexist at low levels before drug therapy is initiated. If virus replication is not fully suppressed by the antiretroviral regimen, these mutants can emerge. Depending on their level of drug resistance, these mutants can either cause overt virologic failure, or, if replication in the presence of drug persists, become more drug resistant by the gradual accumulation of additional resistance mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic barriers to resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV can develop high-level resistance to some drugs with only a single mutation, while other drugs require multiple mutations. Drugs in the former situation are referred to as having a \"low genetic barrier\" to resistance.",
"   </p>",
"   <p>",
"    As an example, a single mutation can lead to high-level",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance. This is also true of the non-nucleoside reverse transcriptase inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    . In contrast, the development of high-level resistance in the protease inhibitor class usually requires the accumulation of multiple mutations. A consequence of these different genetic barriers is that resistance to 3TC or non-nucleoside reverse transcriptase inhibitors usually appears earlier during virologic failure than resistance to most protease inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Regimen potency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potency of an individual drug or a combination of drugs is a crucial determinant of viral load suppression. If viral load is not fully suppressed, continued virus replication in the presence of drug can lead to the accumulation of mutations, leading to the development of virus resistance, even to drugs with a high genetic barrier to resistance.",
"   </p>",
"   <p>",
"    This principal was illustrated in one trial, in which 653 treatment-naive patients were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/4\">",
"     4",
"    </a>",
"    ]. After 48 weeks of follow-up, the emergence of resistance and virologic failure was more common in patients in the nelfinavir arm compared to the lopinavir arm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the cumulative proportion of patients who have been exposed to all three HIV drug classes has increased over time, observational data from a large cohort in Europe suggests that the incidence of triple class resistance has declined and the prevalence of triple class resistance has stabilized to a low level (ie, &lt;3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although protease inhibitors have a high genetic barrier to resistance, this advantage can be lost in the setting of low serum trough concentrations, because virus with low levels of resistance can continue to replicate and accumulate more mutations that lead to higher levels of resistance. This problem can be offset by the use of pharmacokinetic \"boosting\" with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    . Adverse pharmacokinetic interactions that lead to subtherapeutic levels can also promote the development of drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link&amp;anchor=H32#H32\">",
"     \"HIV protease inhibitors\", section on 'Pharmacokinetic boosting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resistance can also result when individual components of an HIV regimen have varying plasma half-lives. In this case, discontinuation of HAART can lead to functional monotherapy. Furthermore, pharmacokinetic profiles can vary significantly in different patient populations. This pharmacokinetic variability was well illustrated in a study of 152 patients who were receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    (EFV), which is metabolized primarily by cytochrome p450 2B6 isoenzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/6\">",
"     6",
"    </a>",
"    ]. A G-to-T polymorphism at position 516 of CYP2B6 was associated with higher plasma EFV concentrations and slower clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/7\">",
"     7",
"    </a>",
"    ]. The study was significant for the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median estimated EFV half-lives varied depending on the patient's genotype. Those patients with a TT genotype had the longest half-life.",
"     </li>",
"     <li>",
"      Therapeutic plasma levels were predicted to be present for a median of 5.8, 7, and 14 days after discontinuation of drug in patients with varying polymorphisms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data have implications for the risk of resistance when the regimen is discontinued, although this study did not directly evaluate the development of EFV resistance after drug discontinuation in patients with different CYP2B6 genotypes.",
"   </p>",
"   <p>",
"    Therapeutic drug monitoring (TDM) is of theoretical utility because of interpatient variability in drug exposure and the possibility that increasing drug exposure might improve treatment responses in patients with drug-resistant HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1\">",
"     1",
"    </a>",
"    ]. Measurement of plasma NRTI concentrations is thought not to be as important clinically due to the intracellular location of their active forms. In contrast, protease inhibitors and NNRTIs are candidates for TDM since serum concentration-response relationships have been well documented. However, the role of TDM in clinical practice remains controversial due to the lack of prospective studies demonstrating that TDM improves clinical outcome in patients with drug resistant HIV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Medication adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonadherence to antiretroviral therapy is closely associated with incomplete viral suppression and the development of drug resistant HIV variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/8\">",
"     8",
"    </a>",
"    ]. It has been proposed that the relationship between adherence and drug resistance is complex and influenced by drug potency, pill burden, and pharmacokinetics, as illustrated below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug-resistant HIV variants developed during treatment with older PI regimens, even with high levels of adherence. The emergence of resistance in these cases presumably occurred because the plasma PI levels achieved, without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      boosting, did not fully suppress viral replication. In contrast, PI-resistant HIV variants are observed uncommonly on ritonavir-boosted PI regimens used in clinical practice today.",
"     </li>",
"     <li>",
"      The NNRTIs",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      lead to the emergence of drug-resistant variants even with low levels of adherence, with NNRTI-resistant variants developing after only a single dose of drug. The selection for NNRTI-resistant variants despite minimal adherence is likely due in part to the long serum half-life of these NNRTIs and their low genetic barrier to resistance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The selection of ART is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of mutations can cause drug resistance. Different drug resistance mutations may have different effects on cross-resistance to other drugs, and on viral replication efficiency or \"fitness\". (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .) In addition, mutations can also interact with each other, sometimes in unexpected ways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Viral fitness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, wild-type virus replicates more efficiently (eg, is more \"fit\") in cell culture than resistant virus, and overgrows mutant strains in the absence of drug selection pressure.",
"   </p>",
"   <p>",
"    In the setting of drug therapy, drug-resistant virus is selected, despite the fact that it is less fit in the absence of drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/11\">",
"     11",
"    </a>",
"    ]. Some investigators have proposed that how frequently a specific drug-resistant variant occurs in patients is influenced by its replication fitness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/3,12-15\">",
"     3,12-15",
"    </a>",
"    ]. In addition, viral variants with reduced fitness have been proposed to be less pathogenic, although studies examining the correlation of HIV replication fitness with clinical outcome have not given consistent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cross-resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sometimes a mutation develops that is unique for a particular drug. An example of this is the D30N mutation that occurs on exposure to the protease inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    ; this signature mutation does not necessarily confer resistance to other protease inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, a single virus mutation, K103N, confers resistance to both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/18\">",
"     18",
"    </a>",
"    ]. Thymidine-associated mutations (TAMs) can cause resistance to AZT, d4T, ddl, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    . A subset of these TAMs also confer resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypersusceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, resistance to one drug can lead to increased susceptibility, or hypersusceptibility, to another drug. For example, the M184V mutation that confers 3TC resistance causes hypersusceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and the TAM T215Y is associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    hypersusceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32797450\">",
"    <span class=\"h2\">",
"     Clinical impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergence of drug resistance may also affect the rate of immunologic recovery. In an observational study of 3537 HIV-infected patients who initiated ART, those with more than one episode of virologic failure had a slower immunologic recovery compared with those without virologic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RATIONALE FOR HIV SUSCEPTIBILITY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of genotypic and phenotypic susceptibility testing leads to better viral suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/23\">",
"     23",
"    </a>",
"    ]. Resistance testing has also been associated with improved survival. An analysis was performed of more than 2699 HIV-infected patients eligible for genotypic and phenotypic testing seen from 1999 through 2005; approximately one-third of the patients had undergone resistance testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/24\">",
"     24",
"    </a>",
"    ]. Within this observational study, resistance testing was associated with improved survival (adjusted HR, 0.69 [95% CI 0.51-0.94]) after controlling for demographics, CD4 cell count, HIV RNA level, and intensity of clinical follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF RESISTANCE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from resistance testing must be interpreted in the context of the patient's clinical status, adherence to therapy, treatment history, viral load, and CD4 cell count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1,25\">",
"     1,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Choosing a regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;When using the results of drug resistance testing, a salvage regimen should be chosen containing three drugs to which the patient's isolate is fully susceptible. If drugs to which the isolate is partially resistant must be included in the regimen, consideration should be given to augmenting the regimen with additional drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Assessing adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of wild-type virus on genotype testing (that is, no evidence of resistance) in a patient who is failing a potent combination antiretroviral regimen should raise suspicion of non-adherence to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Particular care should be taken when adding a drug that has previously been used, even if the most recent testing demonstrates susceptibility to that drug. Currently available resistance tests are relatively insensitive to minority variants (typically &lt;10 to 20 percent of the circulating quasispecies) that may still be present after virologic failure of previously discontinued regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/26\">",
"     26",
"    </a>",
"    ], and phenotypic assays are relatively insensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    (ddI) or d4T resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. Consistent with this, one study demonstrated that a single genotypic resistance test detected resistance less often than serial testing over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cross-resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to one drug may confer decreased susceptibility to another, although this may not be indicated on the test results. As an example, there is support for the existence of cross-resistance between ZDV and either ddI or d4T [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. Depending on the experience of the testing laboratory, the extent of such cross-resistance may be underreported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Expert advice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because our understanding of how best to interpret resistance testing continues to evolve, a specialist experienced in the management of HIV infection and interpretation of drug resistance testing should be consulted. Patterns of mutations can be quite complex, and interpretations can change over time as more information is obtained regarding the relationship between drug resistance mutations and response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     False negative results",
"    </span>",
"    &nbsp;&mdash;&nbsp;False negative results may occur if blood samples are obtained after therapy is stopped because susceptible variants may outgrow the resistant mutants in the absence of drug pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. A minimum viral load of 500 to 1000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    of plasma is usually needed for successful amplification. False negative results at higher viral loads may be due to sequence variation in the viral genome at sites where amplification or sequencing primers hybridize. In these instances, repeating the resistance test with a laboratory that uses a different methodology may lead to a positive result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Replication capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance mutations may affect viral replication efficiency, or \"fitness\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/16\">",
"     16",
"    </a>",
"    ]. An HIV-1 variant with a lower replication capacity may be less virulent and infection with such a variant could theoretically result in slower disease progression, as measured by slower declines in CD4 cells. Some resistance testing reports now also include a replication capacity value. However, there are not sufficient clinical data to recommend the routine use of replication capacity assays in patient management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1,16,34\">",
"     1,16,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     WHEN TO OBTAIN RESISTANCE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the use of drug resistance testing in HIV-infected patients are available, based on recommendations of expert panels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1,25,35\">",
"     1,25,35",
"    </a>",
"    ]. Recommendations for using drug resistance testing assays are summarized in the DHHS Antiretroviral Guidelines for the Treatment of Adults and Adolescents, which can be accessed at",
"    <a class=\"external\" href=\"file://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1\">",
"     file://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment-na&iuml;ve patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of drug resistance is significant and can have a major impact on choice of initial antiretroviral therapy.",
"   </p>",
"   <p>",
"    Studies have shown a prevalence of drug-resistant HIV variants of 8 to 18 percent in treatment-naive patients, many of whom were chronically infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/36-41\">",
"     36-41",
"    </a>",
"    ]. Data from several studies suggest suboptimal treatment responses in patients with baseline resistance mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. Thus, resistance testing is therefore recommended in treatment-na&iuml;ve patients, because of the risk that they may have been infected with a drug-resistant strain.",
"   </p>",
"   <p>",
"    Resistance testing ideally should be part of the initial evaluation of all infected treatment-na&iuml;ve patients, even if therapy is not planned in the near future, because of concerns that drug-resistant strains may be overgrown in time by drug-sensitive strains and therefore become more difficult to detect. If therapy is initially deferred, repeating the genotypic resistance test prior to starting therapy is also recommended, as a superinfection with a resistant strain can occur in the interim if the patient continues high-risk transmission behavior. Results from both tests should be used when considering which regimen to begin.",
"   </p>",
"   <p>",
"    Drug resistance testing should also be performed if a patient who has initiated ART has a suboptimal decline in HIV RNA (eg, detectable viremia after 24 weeks of therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1\">",
"     1",
"    </a>",
"    ]. It is preferential to test for drug resistance while the patient is taking prescribed therapy or, if not possible, within four weeks after discontinuing therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Primary HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance testing should be performed in all patients with primary HIV infection, whether or not treatment will be initiated. In studies of patients with acute and early HIV infection, the prevalence of transmitted drug resistance mutations is about 15 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the decision is made to initiate therapy in a person with acute HIV infection, results of resistance testing at baseline provide guidance in medication selection. Treatment may also be initiated immediately without the benefit of resistance testing results; if necessary, subsequent modifications to the regimen can be made once the resistance test report is available. A genotypic assay is preferred in this setting given the faster turnaround time.",
"   </p>",
"   <p>",
"    If a decision is made not to treat a patient with primary HIV infection, resistance testing is still recommended to optimize documentation of resistance. In the absence of therapy, drug-resistant viruses tend to be replaced by wild-type viruses and may not be fully characterized at a later date. These minority variants may lead to treatment failure in the future if resistance testing is not performed in a timely manner. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment-experienced patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance testing is recommended to maximize the number of drug-sensitive medications in patients who have failed one or more prior regimens. The benefits of resistance testing in selection of ART have been demonstrated in retrospective studies, as well as some prospective clinical trials.",
"   </p>",
"   <p>",
"    In patients with virologic failure, drug resistance testing is recommended in patients on combination ART with HIV RNA levels &gt;1,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1\">",
"     1",
"    </a>",
"    ] . Testing should also be considered in persons with HIV RNA levels &gt;500 but &lt;1,000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    but may be unsuccessful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance testing is recommended to optimize treatment outcomes for the mother and minimize the risk of HIV transmission to the neonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/49\">",
"     49",
"    </a>",
"    ]. Current treatment guidelines support combination ART for pregnant women, if indicated.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    should be avoided due to risks of teratogenicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug resistance testing may also be helpful in women who are postpartum and who may have received limited ART for the sole purpose of preventing perinatal transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CHOICE OF TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotypic testing is recommended as the preferred assay in persons experiencing virologic failure after their first or second antiretroviral regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1\">",
"     1",
"    </a>",
"    ]. Genotypic resistance testing is generally recommended initially because of its lower cost and availability of greater efficacy data from prospective clinical trials. Standard genotypic testing includes testing for mutations in the reverse transcriptase or protease genes. If resistance is suspected to integrase inhibitors, a supplemental genotypic test must be ordered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1\">",
"     1",
"    </a>",
"    ]. No genotypic resistance tests are available for CCR5 antagonists. However, there are genotypic tests available for viral coreceptor usage to determine R5 or X4 tropism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/46/3814?source=see_link\">",
"     \"Clinical trials of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In highly treatment-experienced patients with complicated mutation patterns, obtaining phenotypic resistance testing in addition to genotypic testing may be of benefit in patients with suspected complex drug resistance mutations, which may occur with protease inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/46/3814?source=see_link\">",
"     \"Clinical trials of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Phenotypic testing for viral coreceptor tropism is recommended before initiating the CCR5 inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    . Detection of CXCR4-tropic virus would preclude the use of this drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/46/3814?source=see_link\">",
"     \"Clinical trials of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients failing integrase inhibitor therapy, genotypic testing for integrase strand transfer inhibitor (INSTI) resistance should be considered to determine whether to include drugs from this class in subsequent regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of drug-resistance testing in chronically-infected patients is further supported by a study of its cost-effectiveness in a hypothetical cohort of antiretroviral-naive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32424/abstract/51\">",
"     51",
"    </a>",
"    ]. A cost-effectiveness ratio for resistance testing remained less than $50,000 per quality-adjusted life-year gained, unless the prevalence of resistance was &lt;1 percent, which is substantially lower than most regions in the United States and Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple factors determine the rate at which resistance develops including drug potency, genetic barriers to resistance, pharmacokinetics, medication adherence, and the biology of HIV itself. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Contributing factors to resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effects of drug resistance are complex and may have clinical implications for viral fitness and resistance to individual drugs or drug classes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Consequences of drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-adherence to medications should be strongly suspected in patients with virologic failure who have \"wild-type\" pansensitive virus. However, the associations between resistance and adherence are complex, and the presence of drug-resistant HIV does not rule out poor adherence as a cause of virologic failure. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Interpretation of resistance testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV drug resistance testing is recommended for all antiretroviral-naive patients about to initiate therapy. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment-na&iuml;ve patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV drug resistance testing should also be performed in all treatment-experienced patients who have HIV RNA levels &gt;1000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      while taking antiretroviral therapy. Testing should also be considered in patients with HIV RNA levels &gt;500 but &lt;1000",
"      <span class=\"nowrap\">",
"       copies/mL,",
"      </span>",
"      although testing may be unsuccessful at these low levels. Testing should ideally be obtained while the patient is still taking the failing regimen. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Baseline genotypic resistance testing is recommended in all patients entering medical care, regardless of whether they immediately require antiretroviral therapy.",
"     </li>",
"     <li>",
"      Drug resistance testing is recommended during pregnancy to optimize treatment selection and to decrease the risk of perinatal transmission.",
"     </li>",
"     <li>",
"      Use of a phenotypic assay to characterize the coreceptor tropism of a patient's virus is recommended before initiating a CCR5 inhibitor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of HIV drug resistance testing assays\", section on 'Phenotypic resistance assays'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32918?source=see_link\">",
"       \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of a specific genotypic test for integrase inhibitor resistance is required when resistance to this class of drugs is suspected. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Choice of testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/2\">",
"      Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/3\">",
"      Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/4\">",
"      Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/5\">",
"      Pursuing Later Treatment Options II (PLATO II) project team, Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group, Nakagawa F, et al. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. J Acquir Immune Defic Syndr 2012; 59:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/6\">",
"      Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/7\">",
"      Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/8\">",
"      Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/9\">",
"      Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/10\">",
"      Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/11\">",
"      Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/12\">",
"      Gerondelis P, Archer RH, Palaniappan C, et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities. J Virol 1999; 73:5803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/13\">",
"      Wang J, Dykes C, Domaoal RA, et al. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency. Virology 2006; 348:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/14\">",
"      Collins JA, Thompson MG, Paintsil E, et al. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 2004; 78:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/15\">",
"      Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 1998; 72:3773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/16\">",
"      Dykes C, Demeter LM. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev 2007; 20:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/17\">",
"      Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998; 177:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/18\">",
"      Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001; 75:4999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/19\">",
"      Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/20\">",
"      Shulman NS, Bosch RJ, Mellors JW, et al. Genetic correlates of efavirenz hypersusceptibility. AIDS 2004; 18:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/21\">",
"      Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/22\">",
"      Trotta MP, Cozzi-Lepri A, Ammassari A, et al. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis 2010; 51:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/23\">",
"      Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/24\">",
"      Palella FJ Jr, Armon C, Buchacz K, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med 2009; 151:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/25\">",
"      Hirsch MS, G&uuml;nthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/26\">",
"      Le T, Chiarella J, Simen BB, et al. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 2009; 4:e6079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/27\">",
"      Harrigan PR, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 2005; 191:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/28\">",
"      Demeter LM, Nawaz T, Morse G, et al. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J Infect Dis 1995; 172:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/29\">",
"      Shafer RW, Winters MA, Jellinger RM, Merigan TC. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. J Infect Dis 1996; 174:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/30\">",
"      Montaner JS, Mo T, Raboud JM, et al. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine. J Infect Dis 2000; 181:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/31\">",
"      de Mendoza C, Soriano V, Briones C, et al. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. J Acquir Immune Defic Syndr 2000; 23:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/32\">",
"      Marcelin AG, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005; 49:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/33\">",
"      Desai S, Kyriakides T, Holodniy M, et al. Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy. HIV Clin Trials 2007; 8:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/34\">",
"      Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/35\">",
"      Vandamme AM, S&ouml;nnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/36\">",
"      Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005; 40:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/37\">",
"      Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/38\">",
"      Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/39\">",
"      Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331:1368.",
"     </a>",
"    </li>",
"    <li>",
"     Kim D, Wheeler W, Ziebell R, et al. Prevalence of Transmitted Antiretroviral Drug Resistance among Newly-diagnosed HIV-1-infected Persons, US, 2007. 17th CROI 2010, February 16-19 San Francisco, CA, Abstract #580.",
"    </li>",
"    <li>",
"     Prejean J, Ziebell R, Wheeler W, et al. Prevalence of Mutations Associated with Transmitted Drug Resistant HIV among BED Recent Versus Long-term Infections, US, 2006, US. 17th CROI 2010, February 16-19, San Francisco, CA, Abstract #580; Abstract #581.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/42\">",
"      Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/43\">",
"      Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/44\">",
"      Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/45\">",
"      Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-na&iuml;ve populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/46\">",
"      Yanik EL, Napravnik S, Hurt CB, et al. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/47\">",
"      Jain V, Liegler T, Vittinghoff E, et al. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 2010; 5:e15510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/48\">",
"      Hurt CB, McCoy SI, Kuruc J, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009; 14:673.",
"     </a>",
"    </li>",
"    <li>",
"     Public Health Service Task Force Recommendations for use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. www.AIDSInfo.nih.gov (Accessed on July 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/50\">",
"      Paredes R, Cheng I, Kuritzkes DR, et al. Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS 2010; 24:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32424/abstract/51\">",
"      Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41:1316.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3759 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-BD52B341D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32424=[""].join("\n");
var outline_f31_42_32424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONTRIBUTING FACTORS TO RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HIV biology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic barriers to resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Regimen potency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Medication adherence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONSEQUENCES OF DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Viral fitness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cross-resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypersusceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32797450\">",
"      Clinical impact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RATIONALE FOR HIV SUSCEPTIBILITY TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INTERPRETATION OF RESISTANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Choosing a regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Assessing adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cross-resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Expert advice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      False negative results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Replication capacity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      WHEN TO OBTAIN RESISTANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment-na&iuml;ve patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Primary HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CHOICE OF TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      COST-EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/46/3814?source=related_link\">",
"      Clinical trials of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=related_link\">",
"      Overview of HIV drug resistance testing assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_42_32425="Electroencephalography (EEG) in the diagnosis of seizures and epilepsy";
var content_f31_42_32425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electroencephalography (EEG) in the diagnosis of seizures and epilepsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32425/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32425/contributors\">",
"     Lawrence J Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32425/contributors\">",
"     Hiba Arif, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32425/contributors\">",
"     Jeremy Moeller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32425/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32425/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/42/32425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of epilepsy is often not straightforward, and misdiagnosis is not rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/1\">",
"     1",
"    </a>",
"    ]. A detailed and reliable account of the event by an eyewitness is the most important part of the diagnostic evaluation, but may not be available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electroencephalography (EEG) is an important diagnostic test in evaluating a patient with possible epilepsy. It can provide support for the diagnosis of epilepsy and also assists in classifying the underlying epileptic syndrome.",
"   </p>",
"   <p>",
"    However, there are several reasons why EEG alone cannot be used to make or refute a specific diagnosis of epilepsy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most EEG patterns can be caused by a wide variety of different neurologic diseases.",
"     </li>",
"     <li>",
"      Many diseases can cause more than one type of EEG pattern.",
"     </li>",
"     <li>",
"      Intermittent EEG changes, including interictal epileptiform discharges, can be infrequent and may not appear during the relatively brief period of routine EEG recording.",
"     </li>",
"     <li>",
"      The EEG can be abnormal in some persons with no other evidence of disease.",
"     </li>",
"     <li>",
"      Not all cases of brain disease are associated with an EEG abnormality, particularly if the pathology is small, chronic, or located deep in the brain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to make the best clinical use of EEG in the evaluation of patients with possible epilepsy, the clinician must understand the strengths and weaknesses of EEG, specifically as they relate to the diagnosis of seizures and epilepsy.",
"   </p>",
"   <p>",
"    This topic discusses the use of EEG in the diagnosis of seizures and epilepsy. A more general discussion of EEG, and the use of other diagnostic tests in the evaluation of patients with seizures and epilepsy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical neurophysiology\", section on 'Electroencephalogram'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EEG FINDINGS IN PATIENTS WITH EPILEPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different EEG findings are variably associated with epilepsy. In the setting of potential epilepsy, it is useful to classify EEG abnormalities as epileptiform and nonepileptiform.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examples of epileptiform activity include interictal epileptiform discharges (IEDs), periodic lateralized epileptiform discharges (PLEDs) (",
"      <a class=\"graphic graphic_waveform graphicRef62133 \" href=\"mobipreview.htm?14/26/14761\">",
"       waveform 1",
"      </a>",
"      ), and generalized periodic discharges (GPDs) (",
"      <a class=\"graphic graphic_waveform graphicRef66411 \" href=\"mobipreview.htm?16/9/16537\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Nonepileptiform abnormalities include slowing, which may be diffuse, regional, or localized; amplitude changes or asymmetries; and other deviations from normal patterns. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Slowing'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only epileptiform discharges are associated with epilepsy at rates sufficient to be clinically useful, and only when benign variants have been excluded. Nonspecific (nonepileptiform) EEG abnormalities are relatively common, especially in elderly individuals, patients with migraine, and those on centrally-acting medications. These should not be interpreted as supporting a diagnosis of epilepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Interictal epileptiform discharges",
"    </span>",
"    &nbsp;&mdash;&nbsp;To qualify as an interictal epileptiform discharge (IED), discharges should meet the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They must be paroxysmal and distinct from the patient's normal background activity.",
"     </li>",
"     <li>",
"      They must include an abrupt change in polarity occurring over several milliseconds.",
"     </li>",
"     <li>",
"      The duration of each transient should be less than 200 milliseconds (ms). A spike has a duration of less than 70 ms; sharp waves have a duration between 70 and 200 ms.",
"     </li>",
"     <li>",
"      The discharge must have a physiological field.",
"     </li>",
"     <li>",
"      They must not be one of the known benign variants or normal discharges such as wicket spikes, small sharp spikes, or vertex waves (",
"      <a class=\"graphic graphic_table graphicRef80464 \" href=\"mobipreview.htm?30/23/31100\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef62862 graphicRef78379 graphicRef70492 graphicRef73673 graphicRef51113 graphicRef81768 graphicRef65255 \" href=\"mobipreview.htm?0/10/169\">",
"       waveform 3A-G",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most IEDs are of negative polarity at the scalp, and are followed by a slow wave (ie, a spike-wave complex). While these two features are not required criteria, they are helpful in distinguishing IEDs from other types of paroxysmal activity, including electrode or other artifacts. They also relate closely to the underlying physiological phenomena occurring at the cellular level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37385?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathophysiology of seizures and epilepsy\", section on 'Paroxysmal depolarization shift'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;An IED is found in 20 to 55 percent of persons with epilepsy on a first \"routine\" EEG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. A number of factors can influence the sensitivity of a finding of IED for the diagnosis of epilepsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of EEG studies &mdash; With repeated recordings, the likelihood of finding IEDs increases from 20 to 50 percent to as high as 80 to 90 percent when four or more EEGs are obtained [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/5,6,8-10\">",
"       5,6,8-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      EEG duration &mdash; A routine EEG is 30 to 45 minutes in length. EEG monitoring over several hours to days also increases the yield of the study. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=see_link\">",
"       \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study in an epilepsy monitoring unit, 43 percent of patients with epilepsy had an IED in the first hour of recording, and the yield increased to 89 percent after 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 100 adult patients with confirmed epileptic seizures, EEG monitoring for seven days revealed IEDs in 81 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In another study in an epilepsy monitoring unit, 86 percent of 119 patients with definite epilepsy had IEDs in the first two days, 3 percent of patients developed IEDs after two days; only 12 percent never had IEDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seizure frequency &mdash; More frequent seizures are associated with a higher frequency of IEDs on an EEG tracing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/6,14\">",
"       6,14",
"      </a>",
"      ]. In this regard, a finding of IEDs may also be predictive of seizure recurrence. In a meta-analysis of 11 Class I and II studies of EEG after a first unprovoked seizure in adults, the probability of seizure recurrence in patients with epileptiform EEG abnormalities was 49.5 percent compared to 27.4 percent in those with normal EEGs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Timing in regard to recent seizure &mdash; Clinical seizures are temporally associated with more frequent IEDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/5,6,16\">",
"       5,6,16",
"      </a>",
"      ]. Among 141 patients evaluated after a first seizure, IEDs were observed more often when the EEG was obtained within 24 hours of the seizure than when obtained later (51 versus 34 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/5\">",
"       5",
"      </a>",
"      ]. One study suggested that this phenomenon is more often seen in seizures of medial temporal versus neocortical origin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/17\">",
"       17",
"      </a>",
"      ]. In another case series, early performance of an EEG (within 24 hours of a seizure) appeared to have a similar yield of epileptiform abnormalities as did a later-performed sleep-deprived study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sleep and sleep deprivation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Antiepileptic drug therapy &mdash; There is limited information regarding the suppressant effect of AEDs on IED detection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/19-23\">",
"       19-23",
"      </a>",
"      ]. Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      , and probably",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"       ethosuximide",
"      </a>",
"      reduces the rate of generalized IEDs.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"       Diazepam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      can suppress IEDs acutely, but chronic therapy may have little impact. Another study found that antiepileptic drug (AED) withdrawal was associated with fewer spikes on EEG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epilepsy syndrome &mdash; The EEG is more likely to be abnormal in certain epilepsy syndromes. As examples, IEDs are almost invariably present in children with untreated infantile spasms, Landau-Kleffner syndrome, and benign rolandic epilepsy. While medial temporal lobe epilepsy is usually associated with an abnormal interictal EEG, patients with frontal lobe epilepsy may have a normal interictal EEG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/21,24\">",
"       21,24",
"      </a>",
"      ]. However, the presence of IEDs often influences both the diagnosis of epilepsy itself, as well as the specific epilepsy syndrome; as a result, this may be a source of substantial bias.",
"     </li>",
"     <li>",
"      Specialized techniques &mdash; The use of activation procedures (hyperventilation, photic stimulation, sleep deprivation, induced sleep, and medication withdrawal) and special electrode placement can increase the yield of IEDs on an interictal EEG. Their use is recommended on most follow-up EEGs in order to improve the sensitivity of the test. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Specialized techniques'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Factors that are variably reported to be associated with the prevalence of IEDs in persons with epilepsy include a younger age at the time of EEG, a longer duration of epilepsy, and an earlier age at epilepsy onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/6,14\">",
"       6,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;IEDs are rare in patients without a history of seizures. Studies in healthy flight personnel reveal IEDs in 0.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The prevalence of IEDs has been recorded to be somewhat higher in healthy children (3.5 to 6.5 percent) and in hospitalized adults with neurologic or psychiatric illness (2.0 to 2.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A finding of IEDs is most helpful if the clinical history strongly suggests epileptic seizure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/2\">",
"     2",
"    </a>",
"    ]. However, certain caveats apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pattern of IEDs, along with the patient&rsquo;s age, impacts the specificity of these findings. Spikes and sharp waves are common in normal neonates during quiet (nonREM) sleep, but disappear over the first six to eight weeks of life. In contrast, focal or multifocal IEDs in adults are almost always associated with epilepsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/6,31-34\">",
"       6,31-34",
"      </a>",
"      ]. In children, IEDs are less specific for epilepsy. In particular, central-midtemporal discharges, generalized spike-wave discharges, and photoparoxysmal responses may be asymptomatic manifestations of genetic traits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/25,26,28,35\">",
"       25,26,28,35",
"      </a>",
"      ]. In one series of EEG studies, only 40 percent of children with central-midtemporal spikes had epileptic seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/34,36\">",
"       34,36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The Table (",
"      <a class=\"graphic graphic_table graphicRef78039 \" href=\"mobipreview.htm?36/39/37500\">",
"       table 2",
"      </a>",
"      ) lists IEDs that may be seen on EEG, their associated clinical significance, and their likelihood of association with epilepsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some conditions are associated with the presence of IEDs on EEG, but do not imply epilepsy. These include occipital spikes seen in blind people (especially those who are congenitally blind) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Withdrawal from short-acting barbiturates and benzodiazepines, certain metabolic derangements (eg, hypocalcemia, uremia, dialysis disequilibrium), as well as high drug levels of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , neuroleptics (especially",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , and tricyclic antidepressants have been associated with IEDs even in the absence of accompanying seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/22,38,39\">",
"       22,38,39",
"      </a>",
"      ]. These conditions are also associated with a lower seizure threshold.",
"     </li>",
"     <li>",
"      Inexperienced interpreters of EEG, unaware of benign variants and normal fluctuations that are commonly seen on EEG, can misread EEGs and limit the specificity of the findings (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Pitfalls in interpretation'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Periodic lateralized epileptiform discharges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic lateralized epileptiform discharges (PLEDs) are defined by lateralized, persistent spikes, sharp waves, or sharply contoured slow waves that occur with an almost regular repetition rate, typically 0.5 to 2 Hz (",
"    <a class=\"graphic graphic_waveform graphicRef62133 \" href=\"mobipreview.htm?14/26/14761\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These are most often seen in the setting of acute, relatively large, destructive lesions, such as cerebral infarction or hemorrhage, encephalitis, abscess, or rapidly growing cerebral malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/40-45\">",
"     40-45",
"    </a>",
"    ]. In children, PLEDs are also associated with chronic diffuse encephalopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/46\">",
"     46",
"    </a>",
"    ]. Acute symptomatic seizures are seen in about 70 to 85 percent of patients with PLEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/42,47\">",
"     42,47",
"    </a>",
"    ]. This EEG pattern usually resolves over several days to weeks with recovery from the acute illness. Some of these patients develop remote symptomatic epilepsy.",
"   </p>",
"   <p>",
"    Bilateral independent PLEDs (BIPLEDs) have also been described, most often with acute central nervous system (CNS) infections (especially herpes simplex encephalitis), anoxic encephalopathy, and severe chronic epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/42,48\">",
"     42,48",
"    </a>",
"    ]. This pattern is also highly associated with seizures. Compared to PLEDs, BIPLEDs are associated with more severe cerebral injury, worse neurological status and a worse prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1289732\">",
"    <span class=\"h2\">",
"     Generalized periodic discharges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized periodic discharges (GPDS) (",
"    <a class=\"graphic graphic_waveform graphicRef66411 \" href=\"mobipreview.htm?16/9/16537\">",
"     waveform 2",
"    </a>",
"    ) are less common than PLEDS, but are still often observed in critically ill patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/49\">",
"     49",
"    </a>",
"    ]. In a single-center review of over 3000 continuous EEG recordings, GPDs were present in 4.5 percent of patients and were highly correlated with nonconvulsive seizures and nonconvulsive status epilepticus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/50\">",
"     50",
"    </a>",
"    ]. Specifically, 27 percent of patients with GPDs had evidence of nonconvulsive seizures elsewhere in the same recording, compared with 8 percent of controls without GPDs. Although GPDs have also been described as a postictal pattern after convulsive status epilepticus, they were not associated with convulsive seizures or convulsive status in this study when compared to the matched control group. GPDs at a frequency of greater than 1 Hz sometimes signify nonconvulsive status epilepticus. A similar pattern can be seen in toxic-metabolic encephalopathy (eg, \"triphasic waves\"), Creutzfeldt-Jakob disease, Hashimoto's encephalopathy, and from medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    . Slow GPDS (recurring every 4 to 12 seconds) accompanied by time-locked myoclonus in an awake person are highly characteristic of subacute sclerosing panencephalitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Slowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal slow-wave activity and generalized slowing of background rhythms are common postictal and interictal findings in patients with partial seizures and symptomatic epilepsies. However, they are also frequently seen in other neurologic disorders, especially focal structural lesions, regardless of whether there are associated seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. As an example, two-thirds of patients with continuous, focal, polymorphic, delta activity have a structural lesion, but seizures occur in only about 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/51\">",
"     51",
"    </a>",
"    ]. In patients with no clinical history of neurologic injury and a normal neuroimaging study, focal slowing is more likely to suggest epilepsy.",
"   </p>",
"   <p>",
"    Bilateral, synchronous, slow activity in the delta frequency range, or intermittent rhythmic delta activity, does not usually imply epilepsy. In adults, this pattern usually has an anterior predominance and is known as frontal intermittent rhythmic delta activity (FIRDA). Once thought to be associated primarily with deep midline cerebral lesions, FIRDA is now recognized to be a nonspecific finding that is associated with encephalopathy and neurodegenerative disease, and that can occasionally be seen in normal individuals as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occipital intermittent rhythmic delta activity (OIRDA) is more common in young children and is rarely seen in patients older than 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/55\">",
"     55",
"    </a>",
"    ]. It is a frequent interictal finding in generalized epilepsy syndromes, occurring in 15 to 38 percent of all patients with childhood absence epilepsy and implies a good prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/55-58\">",
"     55-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Temporal intermittent rhythmic delta activity (TIRDA) is a particular form of focal slowing that is more specific for epilepsy. TIRDA is observed in as many as 25 to 40 percent of patients being evaluated for temporal lobe resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. TIRDA is often associated with temporal IEDs and has a high positive predictive value for temporal lobe epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=see_link&amp;anchor=H8#H8\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Mesial temporal lobe epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Epilepsy syndrome diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of seizures and epilepsy can be important for prognosis and treatment. In adult patients, the most important distinction is between primary-generalized and partial epilepsy.",
"   </p>",
"   <p>",
"    The clinical history can be unhelpful or misleading in this regard. As examples, a patient with staring spells may have absence or complex partial seizures, and a patient with generalized convulsions may have primary or secondarily-generalized epilepsy. Although the presence of an aura strongly suggests partial-onset seizures, one study reported that symptoms interpreted by the patient as a seizure aura (often brief, nonspecific dizziness) occurred in up to 70 percent of those with primary generalized epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific interictal EEG findings that are associated with specific epilepsy syndromes are listed in the Table (",
"    <a class=\"graphic graphic_table graphicRef50497 \" href=\"mobipreview.htm?42/39/43644\">",
"     table 3",
"    </a>",
"    ). Clinical correlation between the clinical seizure type and EEG findings is also important. When these agree, this is generally sufficient to distinguish generalized from partial epilepsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, when focal IEDs are strongly lateralized (more than 90 to 95 percent), they predict the side of seizure onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/32\">",
"     32",
"    </a>",
"    ]. However, focal IEDs can manifest as secondary bilateral synchronous discharges, while generalized epilepsy can have fragmentary expression and appear more focal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. As a result it is important to consider the clinical as well as the EEG manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SPECIALIZED TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific methods can be employed to improve the detection of IEDs and the sensitivity of the test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Routine activating techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard routine EEG usually includes hyperventilation and photic stimulation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperventilation increases the rate of generalized discharges in childhood absence epilepsy and other generalized epilepsies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/64\">",
"       64",
"      </a>",
"      ]. It is less productive in partial epilepsies, increasing the yield of focal IEDs by less than 10 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/21,65\">",
"       21,65",
"      </a>",
"      ]. Two studies have suggested that the yield of hyperventilation in generalized epilepsy may also be low, approximately 12 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]. However, this activation procedure is very effort-dependent, and yield may vary as a result. One study in 80 patients undergoing long-term EEG monitoring found that hyperventilation had an activating effect on EEG recording, but only in those patients whose AEDs were being tapered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Photic stimulation induces IEDs in some individuals with idiopathic generalized epilepsy, and infrequently in patients with focal seizures arising from the occipital lobe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/21,64\">",
"       21,64",
"      </a>",
"      ]. A trait of photoparoxysmal response can also run in families, and in this setting in particular, is a less specific finding for epilepsy than spontaneous IEDs. A photoparoxysmal response that is both generalized and sustained (outlasting the period of photic stimulation) and occurs at a different frequency than the photic stimulation is more likely to be associated with epilepsy than when these features are absent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/65\">",
"       65",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In order to maximize the yield of photic stimulation, each laboratory should have a protocol that includes testing at a number of frequencies between 1 Hz and 60 Hz, and patients should be tested with eyes both opened and closed at each frequency, if possible. The technologist should document the patient&rsquo;s clinical response to photic stimulation at each frequency. The procedures for photic stimulation vary widely, although there have been attempts to establish standardized methodology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sleep and sleep deprivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep is a neurophysiologic activator of epilepsy; 20 to 40 percent of epilepsy patients with an initial normal recording will have IEDs on a subsequent recording that includes sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Sleep is sometimes captured on a routine EEG, but sleep deprivation increases this likelihood. Sleep is also usually captured on prolonged EEG monitoring and alternatively, can be induced by administration of a sedative, usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/26/5542?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In a cohort of 92 children aged 2 to 16 years with new-onset seizures, the yield of delayed sleep-deprived EEG was similar to that of an early EEG, done within 2 to 24 hours of the seizure (61 percent had epileptiform abnormalities on sleep deprived EEG, compared to 57 percent on early EEG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sleep deprivation appears to increase IEDs to an extent not fully explained by the greater chance of recording sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/4,33\">",
"     4,33",
"    </a>",
"    ]. One study found that the additional yield of a sleep-deprived EEG was similar whether or not sleep was recorded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/71\">",
"     71",
"    </a>",
"    ]. Another study found that a sleep-deprived EEG had significantly higher yield compared with drug-induced sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/73\">",
"     73",
"    </a>",
"    ]. In this study, the sleep-deprived patients were also more likely to have a seizure during the EEG compared with the sedated patients. The time it takes to perform an EEG with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/26/5542?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    sedation is significantly longer, and in one study was not associated with a higher yield of IED detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/74\">",
"     74",
"    </a>",
"    ]. Melatonin may be superior to chloral hydrate at increasing the rate of detection of IEDs in routine EEGs in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When sleep-deprived EEG was compared to 24-hour ambulatory EEG monitoring in 46 patients with \"presumed epilepsy\", IED detection was similar (24 versus 33 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/34\">",
"     34",
"    </a>",
"    ]. However, clinical seizures were also captured in 15 percent of the ambulatory EEGs and in none of the sleep-deprived EEG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is generally agreed that a follow-up EEG in a patient with possible epilepsy and a normal routine EEG should include sleep. Clinicians can order full or partial sleep deprivation, but it is not clear how much this affects the yield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/4\">",
"     4",
"    </a>",
"    ]. The choice of test (sleep-deprived, sleep with oral sedation, or prolonged EEG monitoring) should be individualized to the patient's circumstances. Because sleep deprivation can be quite disruptive and carries some risk of seizure exacerbation, we generally prefer 24-hour-ambulatory EEG studies over sleep-deprived studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Special electrode placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some highly epileptogenic areas, such as the mesial temporal lobes, are not well explored by the standard scalp electrodes. The classic temporal chain electrodes",
"    <span class=\"nowrap\">",
"     (F7/F8",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     T7/T8)",
"    </span>",
"    lie close to the sylvian fissure and can record activity from both infra- and suprasylvian regions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57579 \" href=\"mobipreview.htm?19/63/20464\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Specialized electrode placement can improve detection of IEDs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57579 \" href=\"mobipreview.htm?19/63/20464\">",
"     image 1",
"    </a>",
"    ). However, these electrodes can be uncomfortable for patients and are associated with increased artifact, which increases the potential for misinterpretation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Pitfalls in interpretation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sphenoidal electrodes are wires inserted through a needle cannula inferior to the zygomatic arch, perpendicular to the sagittal plane, and parallel to the coronal plane, in an attempt to record activity from the anterior tip of the temporal lobe (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57579 \" href=\"mobipreview.htm?19/63/20464\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Nasopharyngeal electrodes (Np1 and Np2) are inserted through the nostrils into the nasopharynx to record from the anterior mesial surface of the temporal lobe (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57579 \" href=\"mobipreview.htm?19/63/20464\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ear electrodes (A1 and A2) are inserted into the ear canal to lie next to the tympanic membrane (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57579 \" href=\"mobipreview.htm?19/63/20464\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Superficial anterior temporal (T1 and T2) electrodes are placed 1 cm above and one-third the distance along the line from the external auditory meatus to the external canthus of the eye.",
"     </li>",
"     <li>",
"      Mandibular notch electrodes (Mn1 and Mn2) are placed 2.5 cm anterior to the external auditory meatus, inferior to the zygomatic arch, at the insertion site for sphenoidal electrodes (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57579 \" href=\"mobipreview.htm?19/63/20464\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Inferior temporal chain electrodes",
"      <span class=\"nowrap\">",
"       (F9/T9/P9",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       F10/T10/P10)",
"      </span>",
"      are an extra chain of three electrodes placed a standard electrode distance inferior to the standard temporal chain and record from the temporal lobes (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57579 \" href=\"mobipreview.htm?19/63/20464\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, sphenoidal electrodes have the highest yield and are associated with considerably less artifact then nasopharyngeal electrodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/76\">",
"     76",
"    </a>",
"    ]. In one study, sphenoidal electrodes detected 99 percent of discharges, compared with a 57 percent yield for nasopharyngeal electrodes and 54 percent yield for ear electrodes. However, these electrodes are invasive and uncomfortable for patients and are not used routinely for diagnostic purposes.",
"   </p>",
"   <p>",
"    The superficial anterior temporal and mandibular notch electrodes are slightly less sensitive than sphenoidal electrodes, but are noninvasive and are equivalent or superior in sensitivity and patient comfort to the nasopharyngeal, mandibular notch subdermal (also known as minisphenoidal), and ear electrodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/77-80\">",
"     77-80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PITFALLS IN INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Misinterpretation of EEG findings or over-reliance on the EEG frequently contributes to misdiagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/9,16,70,71,81\">",
"     9,16,70,71,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to remember that a normal EEG never rules out epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/82\">",
"     82",
"    </a>",
"    ]. Even with repeated EEGs, use of specialized techniques, or prolonged monitoring, a significant number of patients with epilepsy (10 to 20 percent) will have not have IEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/72,82\">",
"     72,82",
"    </a>",
"    ]. Even ictal recordings may not have an identifiable scalp correlate in many frontal lobe seizures, as well as in simple partial seizures from any location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also important to note that \"abnormal\" EEG does not define epilepsy; most abnormal findings are nonspecific. IEDs are the most specific finding for epilepsy, but these can occur in about 0.5 percent of healthy adults and in 1.9 to 6.5 percent of normal children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/30,72\">",
"     30,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also wide variation in how EEGs are interpreted. When EEGs are read by clinicians without special training, a number of benign or normal patterns are often misinterpreted as epileptiform [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/70,71,81,83\">",
"     70,71,81,83",
"    </a>",
"    ]. These include (",
"    <a class=\"graphic graphic_table graphicRef80464 \" href=\"mobipreview.htm?30/23/31100\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/71,84,85\">",
"     71,84,85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign epileptiform transients of sleep (BETS), also termed small sharp spikes (SSS) (",
"      <a class=\"graphic graphic_waveform graphicRef62862 \" href=\"mobipreview.htm?20/50/21287\">",
"       waveform 3A",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wicket spikes (",
"      <a class=\"graphic graphic_waveform graphicRef78379 \" href=\"mobipreview.htm?31/7/31860\">",
"       waveform 3B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rhythmic midtemporal theta of drowsiness (psychomotor variant) (",
"      <a class=\"graphic graphic_waveform graphicRef70492 \" href=\"mobipreview.htm?25/43/26296\">",
"       waveform 3C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Six-Hz \"phantom\" spike and wave complex (",
"      <a class=\"graphic graphic_waveform graphicRef73673 \" href=\"mobipreview.htm?28/41/29338\">",
"       waveform 3D",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Subclinical rhythmic EEG discharge in adults (SREDA) (",
"      <a class=\"graphic graphic_waveform graphicRef51113 \" href=\"mobipreview.htm?2/12/2246\">",
"       waveform 3E",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Positive occipital sharp transients of sleep (POSTS) (",
"      <a class=\"graphic graphic_waveform graphicRef81768 \" href=\"mobipreview.htm?28/62/29674\">",
"       waveform 3F",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Breach rhythm (",
"      <a class=\"graphic graphic_waveform graphicRef65255 \" href=\"mobipreview.htm?1/25/1432\">",
"       waveform 3G",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperventilation-induced high voltage paroxysmal slow waves",
"     </li>",
"     <li>",
"      Artifacts (such as over-filtered muscle potentials)",
"     </li>",
"     <li>",
"      Repetitive vertex waves, especially in children",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeating the EEG or having it reinterpreted at a tertiary epilepsy center by a board-certified electroencephalographer can be helpful. One meta-analysis found that a more restrictive interpretation style that limits false positive results improves diagnostic accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/86\">",
"     86",
"    </a>",
"    ]. However, even among experienced, board-certified neurophysiologists, interobserver agreement is only moderate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32425/abstract/2,7,87\">",
"     2,7,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/0/18434?source=see_link\">",
"       \"Patient information: EEG (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/40/43650?source=see_link\">",
"       \"Patient information: Epilepsy in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/54/38754?source=see_link\">",
"       \"Patient information: Epilepsy in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroencephalography (EEG) remains an important diagnostic test in evaluating a patient with possible epilepsy, providing evidence that helps confirm or refute the diagnosis. EEG also assists in classifying the underlying epileptic syndrome and thereby guides management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single routine EEG has low sensitivity for detection of interictal epileptiform discharges (IED) (20 to 50 percent) for patients with epilepsy. The sensitivity can be increased by repeating the study, recording for a longer period of time (such as overnight), including a recording of sleep (spontaneous, after sleep deprivation, or via administration of a sedative), performing the EEG within 24 hours of a seizure, and by using special electrodes for temporal lobe epilepsy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sensitivity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Specialized techniques'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A normal EEG, however, can never rule out epilepsy; 10 to 20 percent of patients with definite epilepsy never have IEDs.",
"     </li>",
"     <li>",
"      Overall, the specificity of IEDs for epilepsy is high, more than 90 percent in adults. However, inexperienced EEG interpreters can mistake artifact or benign EEG patterns for IEDs, lowering the specificity of the study. The specificity of this finding is also influenced by the pattern of IEDs, and by the patient's age, family history, and comorbid conditions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Specificity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Pitfalls in interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periodic lateralized epileptiform discharges (PLEDs) are usually seen in the setting of acute, relatively large cerebral injury, such as stroke, encephalitis, or rapidly growing cerebral malignancies. Acute symptomatic seizures are common in patients with PLEDs. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Periodic lateralized epileptiform discharges'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Generalized or focal slowing on EEG is nonspecific and does not suggest epilepsy. One exception is the pattern of temporally-located intermittent rhythmic delta activity (TIRDA), which is highly associated with temporal lobe epilepsy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Slowing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/1\">",
"      Scheepers B, Clough P, Pickles C. The misdiagnosis of epilepsy: findings of a population study. Seizure 1998; 7:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/2\">",
"      van Donselaar CA, Stroink H, Arts WF, Dutch Study Group of Epilepsy in Childhood. How confident are we of the diagnosis of epilepsy? Epilepsia 2006; 47 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     Buzsaki, G, Traub, RD, Pedley, TA. The Cellular Basis of EEG Activity. In: Current Practice of Clinical Electroencephalography. Ebersole, JS, Pedley, TA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2003. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/4\">",
"      Glick TH. The sleep-deprived electroencephalogram: evidence and practice. Arch Neurol 2002; 59:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/5\">",
"      King MA, Newton MR, Jackson GD, et al. Epileptology of the first-seizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients. Lancet 1998; 352:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/6\">",
"      Marsan CA, Zivin LS. Factors related to the occurrence of typical paroxysmal abnormalities in the EEG records of epileptic patients. Epilepsia 1970; 11:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/7\">",
"      van Donselaar CA, Schimsheimer RJ, Geerts AT, Declerck AC. Value of the electroencephalogram in adult patients with untreated idiopathic first seizures. Arch Neurol 1992; 49:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/8\">",
"      Doppelbauer A, Zeitlhofer J, Zifko U, et al. Occurrence of epileptiform activity in the routine EEG of epileptic patients. Acta Neurol Scand 1993; 87:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/9\">",
"      Goodin DS, Aminoff MJ. Does the interictal EEG have a role in the diagnosis of epilepsy? Lancet 1984; 1:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/10\">",
"      Salinsky M, Kanter R, Dasheiff RM. Effectiveness of multiple EEGs in supporting the diagnosis of epilepsy: an operational curve. Epilepsia 1987; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/11\">",
"      Narayanan JT, Labar DR, Schaul N. Latency to first spike in the EEG of epilepsy patients. Seizure 2008; 17:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/12\">",
"      Walczak, T, Scheuer, M, Resor, S, Pedley, T. Prevalence and features of epilepsy without interictal epileptiform discharges. Neurology 1993; 43:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/13\">",
"      Friedman DE, Hirsch LJ. How long does it take to make an accurate diagnosis in an epilepsy monitoring unit? J Clin Neurophysiol 2009; 26:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/14\">",
"      Janszky J, Hoppe M, Clemens Z, et al. Spike frequency is dependent on epilepsy duration and seizure frequency in temporal lobe epilepsy. Epileptic Disord 2005; 7:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/15\">",
"      Krumholz A, Wiebe S, Gronseth G, et al. Practice Parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2007; 69:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/16\">",
"      Gotman J, Marciani MG. Electroencephalographic spiking activity, drug levels, and seizure occurrence in epileptic patients. Ann Neurol 1985; 17:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/17\">",
"      Spencer SS, Goncharova II, Duckrow RB, et al. Interictal spikes on intracranial recording: behavior, physiology, and implications. Epilepsia 2008; 49:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/18\">",
"      Sadleir LG, Scheffer IE. Optimizing electroencephalographic studies for epilepsy diagnosis in children with new-onset seizures. Arch Neurol 2010; 67:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/19\">",
"      Bruni J, Wilder BJ, Bauman AW, Willmore LJ. Clinical efficacy and long-term effects of valproic acid therapy on spike-and-wave discharges. Neurology 1980; 30:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/20\">",
"      Schmidt D. The influence of antiepileptic drugs on the electroencephalogram: a review of controlled clinical studies. Electroencephalogr Clin Neurophysiol Suppl 1982; 36:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/21\">",
"      Pillai J, Sperling MR. Interictal EEG and the diagnosis of epilepsy. Epilepsia 2006; 47 Suppl 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     Van Cott, AC, Brenner, RP. Drug Effects and Toxic Encephalopathy. In: Current practice of clinical electroencephalograhy, Ebersole, JS, Pedley, TA (Eds), Lippincott Williams and Wilkins, Philadephia 2003 p.463.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/23\">",
"      Specchio N, Boero G, Michelucci R, et al. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy. Epilepsia 2008; 49:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/24\">",
"      Verma A, Radtke R. EEG of partial seizures. J Clin Neurophysiol 2006; 23:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/25\">",
"      Bennett DR. Spike-wave complexes in \"normal\" flying personnel. Aerosp Med 1967; 38:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/26\">",
"      Gregory RP, Oates T, Merry RT. Electroencephalogram epileptiform abnormalities in candidates for aircrew training. Electroencephalogr Clin Neurophysiol 1993; 86:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/27\">",
"      Zivin L, Marsan CA. Incidence and prognostic significance of \"epileptiform\" activity in the eeg of non-epileptic subjects. Brain 1968; 91:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/28\">",
"      Cavazzuti GB, Cappella L, Nalin A. Longitudinal study of epileptiform EEG patterns in normal children. Epilepsia 1980; 21:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/29\">",
"      Bridgers SL. Epileptiform abnormalities discovered on electroencephalographic screening of psychiatric inpatients. Arch Neurol 1987; 44:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/30\">",
"      Borusiak P, Zilbauer M, Jenke AC. Prevalence of epileptiform discharges in healthy children--new data from a prospective study using digital EEG. Epilepsia 2010; 51:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/31\">",
"      Hughes JR. Long-term clinical and EEG changes in patients with epilepsy. Arch Neurol 1985; 42:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/32\">",
"      Chung MY, Walczak TS, Lewis DV, et al. Temporal lobectomy and independent bitemporal interictal activity: what degree of lateralization is sufficient? Epilepsia 1991; 32:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/33\">",
"      Fountain NB, Kim JS, Lee SI. Sleep deprivation activates epileptiform discharges independent of the activating effects of sleep. J Clin Neurophysiol 1998; 15:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/34\">",
"      Liporace J, Tatum W 4th, Morris GL 3rd, French J. Clinical utility of sleep-deprived versus computer-assisted ambulatory 16-channel EEG in epilepsy patients: a multi-center study. Epilepsy Res 1998; 32:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/35\">",
"      Eeg-Olofsson O, Peters&eacute;n I, Selld&eacute;n U. The development of the electroencephalogram in normal children from the age of 1 through 15 years. Paroxysmal activity. Neuropadiatrie 1971; 2:375.",
"     </a>",
"    </li>",
"    <li>",
"     Kellaway, P. The incidence, significance and natural history of spike foci in children. In: Current clinical neurophysiology: update on EEG and evoked potentials, Henry, C (Ed), Elsevier, Amsterdam 1981. p.151.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/37\">",
"      Wong VC. Cortical blindness in children: a study of etiology and prognosis. Pediatr Neurol 1991; 7:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/38\">",
"      Malow BA, Reese KB, Sato S, et al. Spectrum of EEG abnormalities during clozapine treatment. Electroencephalogr Clin Neurophysiol 1994; 91:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/39\">",
"      Hughes JR, Schreeder MT. EEG in dialysis encephalopathy. Neurology 1980; 30:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/40\">",
"      CHATRIAN GE, SHAW CM, LEFFMAN H. THE SIGNIFICANCE OF PERIODIC LATERALIZED EPILEPTIFORM DISCHARGES IN EEG: AN ELECTROGRAPHIC, CLINICAL AND PATHOLOGICAL STUDY. Electroencephalogr Clin Neurophysiol 1964; 17:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/41\">",
"      Markand ON, Daly DD. Pseudoperiodic lateralized paroxysmal discharges in electroencephalogram. Neurology 1971; 21:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/42\">",
"      Fitzpatrick W, Lowry N. PLEDs: clinical correlates. Can J Neurol Sci 2007; 34:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/43\">",
"      Gurer G, Yemisci M, Saygi S, Ciger A. Structural lesions in periodic lateralized epileptiform discharges (PLEDs). Clin EEG Neurosci 2004; 35:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/44\">",
"      Baykan B, Kinay D, G&ouml;kyigit A, G&uuml;rses C. Periodic lateralized epileptiform discharges: association with seizures. Seizure 2000; 9:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/45\">",
"      Orta DS, Chiappa KH, Quiroz AZ, et al. Prognostic implications of periodic epileptiform discharges. Arch Neurol 2009; 66:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/46\">",
"      PeBenito R, Cracco JB. Periodic lateralized epileptiform discharges in infants and children. Ann Neurol 1979; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/47\">",
"      Snodgrass SM, Tsuburaya K, Ajmone-Marsan C. Clinical significance of periodic lateralized epileptiform discharges: relationship with status epilepticus. J Clin Neurophysiol 1989; 6:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/48\">",
"      de la Paz D, Brenner RP. Bilateral independent periodic lateralized epileptiform discharges. Clinical significance. Arch Neurol 1981; 38:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/49\">",
"      Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol 2005; 22:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/50\">",
"      Foreman B, Claassen J, Abou Khaled K, et al. Generalized periodic discharges in the critically ill: a case-control study of 200 patients. Neurology 2012; 79:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/51\">",
"      Gilmore PC, Brenner RP. Correlation of EEG, computerized tomography, and clinical findings. Study of 100 patients with focal delta activity. Arch Neurol 1981; 38:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/52\">",
"      Maytal J, Novak GP, Knobler SB, Schaul N. Neuroradiological manifestations of focal polymorphic delta activity in children. Arch Neurol 1993; 50:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/53\">",
"      Marshall DW, Brey RL, Morse MW. Focal and/or lateralized polymorphic delta activity. Association with either 'normal' or 'nonfocal' computed tomographic scans. Arch Neurol 1988; 45:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/54\">",
"      Watemberg N, Alehan F, Dabby R, et al. Clinical and radiologic correlates of frontal intermittent rhythmic delta activity. J Clin Neurophysiol 2002; 19:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/55\">",
"      Dalby, MA. Epilepsy and 3 per second spike and wave rhythms. A clinical, electroencephalographic and prognostic analysis of 346 patients. Acta Neurol Scand 1969; Suppl 40:3+.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/56\">",
"      Holmes GL, McKeever M, Adamson M. Absence seizures in children: clinical and electroencephalographic features. Ann Neurol 1987; 21:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/57\">",
"      Watemberg N, Linder I, Dabby R, et al. Clinical correlates of occipital intermittent rhythmic delta activity (OIRDA) in children. Epilepsia 2007; 48:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/58\">",
"      Gullapalli D, Fountain NB. Clinical correlation of occipital intermittent rhythmic delta activity. J Clin Neurophysiol 2003; 20:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/59\">",
"      Di Gennaro G, Quarato PP, Onorati P, et al. Localizing significance of temporal intermittent rhythmic delta activity (TIRDA) in drug-resistant focal epilepsy. Clin Neurophysiol 2003; 114:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/60\">",
"      Geyer JD, Bilir E, Faught RE, et al. Significance of interictal temporal lobe delta activity for localization of the primary epileptogenic region. Neurology 1999; 52:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/61\">",
"      Boylan LS, Labovitz DL, Jackson SC, et al. Auras are frequent in idiopathic generalized epilepsy. Neurology 2006; 67:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/62\">",
"      International League Against Epilepsy. Electrophysiology. Epilepsia 2003; 44 Suppl 6:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/63\">",
"      Worrell GA, Lagerlund TD, Buchhalter JR. Role and limitations of routine and ambulatory scalp electroencephalography in diagnosing and managing seizures. Mayo Clin Proc 2002; 77:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/64\">",
"      Seneviratne U, Cook M, D'Souza W. The electroencephalogram of idiopathic generalized epilepsy. Epilepsia 2012; 53:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/65\">",
"      Mendez OE, Brenner RP. Increasing the yield of EEG. J Clin Neurophysiol 2006; 23:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/66\">",
"      Holmes MD, Dewaraja AS, Vanhatalo S. Does hyperventilation elicit epileptic seizures? Epilepsia 2004; 45:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/67\">",
"      Raybarman C. Is hyperventilation an effective ''activating'' procedure in routine clinical EEG studies in children? J Child Neurol 2009; 24:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/68\">",
"      Jonas J, Vignal JP, Baumann C, et al. Effect of hyperventilation on seizure activation: potentiation by antiepileptic drug tapering. J Neurol Neurosurg Psychiatry 2011; 82:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/69\">",
"      Kasteleijn-Nolst Trenit&eacute; D, Rubboli G, Hirsch E, et al. Methodology of photic stimulation revisited: updated European algorithm for visual stimulation in the EEG laboratory. Epilepsia 2012; 53:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/70\">",
"      Tartara A, Moglia A, Manni R, Corbellini C. EEG findings and sleep deprivation. Eur Neurol 1980; 19:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/71\">",
"      Roupakiotis SC, Gatzonis SD, Triantafyllou N, et al. The usefulness of sleep and sleep deprivation as activating methods in electroencephalographic recording: contribution to a long-standing discussion. Seizure 2000; 9:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/72\">",
"      Mattson RH, Pratt KL, Calverley JR. Electroencephalograms of epileptics following sleep deprivation. Arch Neurol 1965; 13:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/73\">",
"      Leach JP, Stephen LJ, Salveta C, Brodie MJ. Which electroencephalography (EEG) for epilepsy? The relative usefulness of different EEG protocols in patients with possible epilepsy. J Neurol Neurosurg Psychiatry 2006; 77:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/74\">",
"      Britton JW, Kosa SC. The clinical value of chloral hydrate in the routine electroencephalogram. Epilepsy Res 2010; 88:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/75\">",
"      Ashrafi MR, Mohammadi M, Tafarroji J, et al. Melatonin versus chloral hydrate for recording sleep EEG. Eur J Paediatr Neurol 2010; 14:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/76\">",
"      Sperling MR, Mendius JR, Engel J Jr. Mesial temporal spikes: a simultaneous comparison of sphenoidal, nasopharyngeal, and ear electrodes. Epilepsia 1986; 27:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/77\">",
"      SILVERMAN D. The anterior temporal electrode and the ten-twenty system. Electroencephalogr Clin Neurophysiol 1960; 12:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/78\">",
"      Goodin DS, Aminoff MJ, Laxer KD. Detection of epileptiform activity by different noninvasive EEG methods in complex partial epilepsy. Ann Neurol 1990; 27:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/79\">",
"      Homan RW, Jones MC, Rawat S. Anterior temporal electrodes in complex partial seizures. Electroencephalogr Clin Neurophysiol 1988; 70:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/80\">",
"      Sadler RM, Goodwin J. Multiple electrodes for detecting spikes in partial complex seizures. Can J Neurol Sci 1989; 16:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/81\">",
"      Benbadis SR, Tatum WO. Overintepretation of EEGs and misdiagnosis of epilepsy. J Clin Neurophysiol 2003; 20:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/82\">",
"      Fowle AJ, Binnie CD. Uses and abuses of the EEG in epilepsy. Epilepsia 2000; 41 Suppl 3:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/83\">",
"      Krauss GL, Abdallah A, Lesser R, et al. Clinical and EEG features of patients with EEG wicket rhythms misdiagnosed with epilepsy. Neurology 2005; 64:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/84\">",
"      Tatum WO 4th, Husain AM, Benbadis SR, Kaplan PW. Normal adult EEG and patterns of uncertain significance. J Clin Neurophysiol 2006; 23:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/85\">",
"      Mushtaq R, Van Cott AC. Benign EEG variants. Am J Electroneurodiagnostic Technol 2005; 45:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/86\">",
"      Gilbert DL, Sethuraman G, Kotagal U, Buncher CR. Meta-analysis of EEG test performance shows wide variation among studies. Neurology 2003; 60:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32425/abstract/87\">",
"      Williams GW, L&uuml;ders HO, Brickner A, et al. Interobserver variability in EEG interpretation. Neurology 1985; 35:1714.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2233 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32425=[""].join("\n");
var outline_f31_42_32425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EEG FINDINGS IN PATIENTS WITH EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Interictal epileptiform discharges",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Sensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Specificity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Periodic lateralized epileptiform discharges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1289732\">",
"      Generalized periodic discharges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Slowing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Epilepsy syndrome diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SPECIALIZED TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Routine activating techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sleep and sleep deprivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Special electrode placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PITFALLS IN INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2233\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2233|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/63/20464\" title=\"diagnostic image 1\">",
"      Special EEG electrodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2233|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/23/31100\" title=\"table 1\">",
"      Benign EEG variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/39/37500\" title=\"table 2\">",
"      EEG predictors of epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/39/43644\" title=\"table 3\">",
"      EEG findings in specific epilepsy syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2233|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?14/26/14761\" title=\"waveform 1\">",
"      EEG periodic lateralized epileptiform discharges PLEDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?16/9/16537\" title=\"waveform 2\">",
"      Generalized periodic epileptiform discharges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?20/50/21287\" title=\"waveform 3A\">",
"      EEG Small sharp spikes or BETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?31/7/31860\" title=\"waveform 3B\">",
"      EEG Wicket spikes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?25/43/26296\" title=\"waveform 3C\">",
"      EEG Rhythmic midtemporal theta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?28/41/29338\" title=\"waveform 3D\">",
"      EEG 6 Hz spike and wave",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?2/12/2246\" title=\"waveform 3E\">",
"      EEG Subclinical rhythmic EEG discharge of adults SREDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?28/62/29674\" title=\"waveform 3F\">",
"      EEG Positive occipital sharp transients of sleep POSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?1/25/1432\" title=\"waveform 3G\">",
"      EEG Breach rhythm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37385?source=related_link\">",
"      Pathophysiology of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/0/18434?source=related_link\">",
"      Patient information: EEG (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/40/43650?source=related_link\">",
"      Patient information: Epilepsy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/54/38754?source=related_link\">",
"      Patient information: Epilepsy in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=related_link\">",
"      Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_42_32426="Disorders affecting the spinal cord";
var content_f31_42_32426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Disorders affecting the spinal cord",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32426/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32426/contributors\">",
"     Andrew Eisen, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32426/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32426/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/42/32426/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/42/32426/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/42/32426/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologies that affect the spinal cord are diverse. In addition to trauma, common etiologies of myelopathy include autoimmune, infectious, neoplastic, vascular, and hereditary-degenerative diseases. The relative incidence of each of these entities depends in large part upon the clinical setting. In a regional neuroscience center in the United Kingdom, the most common cause of spastic paraparesis or quadriparesis among 585 patients was cervical spondylotic myelopathy (24 percent), followed by tumor (16 percent), multiple sclerosis (18 percent), and motor neuron disease (4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review some of the more common and important causes of nontraumatic spinal cord dysfunction. Clinical features of the more common of these disorders are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef50336 \" href=\"mobipreview.htm?6/0/6157\">",
"     table 1",
"    </a>",
"    ). Traumatic spinal cord injury and the anatomy and clinical localization of spinal cord disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFLAMMATORY DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transverse myelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transverse myelitis (TM) is a segmental spinal cord injury caused by acute inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. TM is uncommon, with an approximate incidence of between one to five cases per million population annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of TM are idiopathic and presumably result from an autoimmune process; up to half of these patients have a preceding infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. TM can also occur in multiple sclerosis (MS) and can be the presenting demyelinating event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/9\">",
"     9",
"    </a>",
"    ]. Neuromyelitis optica or Devic's disease is a disorder related to MS, in which demyelinating events are limited to the optic nerve and spinal cord. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link&amp;anchor=H25#H25\">",
"     \"Diagnosis of multiple sclerosis in adults\", section on 'Neuromyelitis optica and optic-spinal MS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TM is also associated with connective tissue diseases, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/6,10,11\">",
"       6,10,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mixed connective tissue disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sjogren's syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/6,13,14\">",
"       6,13,14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Scleroderma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antiphospholipid antibody syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ankylosing spondylitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inflammation of TM is generally restricted to one or two segments, usually in the thoracic cord. Symptoms typically develop rapidly over several hours; approximately 37 percent of patients worsen maximally within 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/18\">",
"     18",
"    </a>",
"    ]. Occasionally patients worsen more slowly, over several weeks. Typically the inflammation is bilateral, producing weakness and multimodality sensory disturbance below the level of the lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Unilateral syndromes (eg, Brown Sequard) have been described as well. Almost all patients develop leg weakness of varying severity. Arm weakness also occurs if the lesion is in the cervical cord. In addition to diminished sensation, pain and tingling are common and frequently include a tight banding or girdle-like sensation around the trunk, which may be very sensitive to touch. Back and radicular pain are also common. Bowel and bladder dysfunction, reflective of autonomic involvement, also occur.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) of the involved section of the spinal cord shows gadolinium-enhancing signal abnormality, usually extending over one or more cord segments (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73197 \" href=\"mobipreview.htm?12/9/12439\">",
"     image 1",
"    </a>",
"    ). [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/5,8,19,20\">",
"     5,8,19,20",
"    </a>",
"    ]. The cord often appears swollen at these levels. Cerebrospinal fluid (CSF) is abnormal in half of patients, with elevated protein level (usually 100 to 120",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mL) and moderate lymphocytosis (usually &lt;100",
"    <span class=\"nowrap\">",
"     /mm3).",
"    </span>",
"    Glucose levels are normal. Oligoclonal bands are usually not present in isolated TM, and when present suggest a higher risk of subsequent MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/5,21\">",
"     5,21",
"    </a>",
"    ]. Other studies can help delineate the underlying cause (",
"    <a class=\"graphic graphic_table graphicRef65585 \" href=\"mobipreview.htm?33/47/34557\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most patients with idiopathic TM have at least a partial recovery, which usually begins within one to three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/22\">",
"     22",
"    </a>",
"    ]. Some degree of persistent disability is common, occurring in about 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/8,22\">",
"     8,22",
"    </a>",
"    ]. Significant recovery is unlikely if there is no improvement by three months. A very rapid onset with complete paraplegia and spinal shock have been associated with poorer outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/6,22,23\">",
"     6,22,23",
"    </a>",
"    ]. TM is generally a monophasic illness. However, a small percentage of patients may suffer a recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While patients are often treated with parenteral corticosteroid therapy, there is limited evidence that this approach alters outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/6,8,22\">",
"     6,8,22",
"    </a>",
"    ]. Patients with TM associated with systemic autoimmune disease may be more likely to receive treatment corticosteroids and other immunosuppressive and immunomodulatory therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MS is more likely to develop in those with partial and asymmetric cord involvement versus a complete cord syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. A finding of demyelinating lesions on brain MRI also identifies those at higher risk for MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis of multiple sclerosis in adults\", section on 'Acute and subacute transverse myelitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The granulomatous inflammation of sarcoidosis can affect the spinal cord and produce an acute or subacute segmental myelopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/6,29-31\">",
"     6,29-31",
"    </a>",
"    ]. The lesions can be extramedullary or intramedullary, and can involve the cauda equina as well as the cord. MRI signal abnormalities are not specific; neurosarcoid lesions can appear similar to transverse myelitis or can resemble a tumor. CSF evaluation usually shows elevated protein",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pleocytosis. Hilar lymphadenopathy may suggest the diagnosis; however, serum and CSF angiotensin converting enzyme levels are neither sensitive nor specific for neurosarcoidosis. Patients with neurologic sarcoidosis are generally treated with corticosteroids and other immunomodulatory agents and can improve. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Paraneoplastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of distinct paraneoplastic syndromes involving the spinal cord have been described. These rare syndromes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motor neuron syndrome &mdash; a subacute, progressive, painless, and often asymmetric lower motor neuron weakness, most often associated with lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute necrotizing myelopathy &mdash; a rapidly ascending syndrome of sensory deficits, sphincter dysfunction, and flaccid or spastic paraplegia or quadriplegia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subacute sensory neuronopathy &mdash; an inflammatory disorder affecting the dorsal root ganglia, producing progressive loss of sensory modalities, leading to prominent ataxia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/34\">",
"       34",
"      </a>",
"      ]. This is most often associated with small cell lung cancer and anti-Hu antibodies.",
"     </li>",
"     <li>",
"      Encephalomyelitis &mdash; a diffuse involvement of brain and spinal cord regions, in which cerebral manifestations frequently overshadow the myelopathy. Several syndromes are described.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6583?source=see_link\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Epidural abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal epidural abscess is a rare disease, occurring in only 1 patient per 10,000 admitted to the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/35\">",
"     35",
"    </a>",
"    ]. The infection can originate via contiguous spread from infections of skin and soft tissues or as a complication of spinal surgery and other invasive procedures, including indwelling epidural catheters. Other cases of epidural abscess arise from a remote site via the bloodstream. Diabetes, alcoholism, and human immunodeficiency virus (HIV) infection are risk factors.",
"   </p>",
"   <p>",
"    The most common pathogen is Staphylococcus aureus, which accounts for about two-thirds of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/35\">",
"     35",
"    </a>",
"    ]. Damage to the spinal cord can be caused by direct compression of neural elements or arterial blood supply, thrombosis and thrombophlebitis of nearby veins, focal vasculitis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacterial toxins and mediators of inflammation. The classic clinical triad consists of fever, spinal pain, and neurologic deficits. However, only a few patients have all three components at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/36\">",
"     36",
"    </a>",
"    ]. The rate of neurologic progression is highly variable.",
"   </p>",
"   <p>",
"    Imaging of the spinal column is imperative on first suspicion of the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/36\">",
"     36",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) is the preferred test and is highly sensitive for this diagnosis. Blood cultures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspirate of abscess contents are ordered to identify the etiologic organism. Surgical decompression and drainage with systemic antibiotic therapy is the treatment of choice for most patients. Because the preoperative neurologic deficit is an important predictor of final neurologic outcome, early diagnosis and treatment are imperative.",
"   </p>",
"   <p>",
"    This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/40/17033?source=see_link\">",
"     \"Epidural abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute viral myelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two distinct syndromes of spinal cord involvement are associated with acute viral disease. In the first, the virus targets the gray matter of the spinal cord, producing acute lower motor neuron disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/37\">",
"     37",
"    </a>",
"    ]. These viruses include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteroviruses, such as poliovirus, coxsackie virus, and enterovirus 71 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Flaviviruses, such as West Nile virus and Japanese encephalitis virus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Viral invasion of the anterior horn cells occurs as part of an acute viral illness, usually with fever, headache, and meningismus, and produces asymmetrical flaccid weakness with reduced or absent reflexes and few sensory symptoms or signs. MRI often shows hyperintensities in the anterior horns of the spinal cord on T2-weighted imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/38,42\">",
"     38,42",
"    </a>",
"    ]. Cerebrospinal fluid (CSF) analysis demonstrates a moderate pleocytosis. These features help to distinguish this form of viral myelitis from Guillain-Barr&eacute; syndrome, which usually produces symmetric deficits, with no MRI abnormalities, and is associated with elevated CSF protein levels without pleocytosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Focal or segmental depletion of spinal motor neurons has been described at autopsy, reflecting the observed pattern of neurologic deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The prognosis for recovery is variable. Treatment is supportive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/47/22264?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of West Nile virus infection\", section on 'Neuroinvasive disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Acute paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second form of viral myelitis has clinical and diagnostic test features that are similar to transverse myelitis. Associated viruses include cytomegalovirus, varicella zoster, herpes simplex virus, hepatitis C, and Epstein Barr virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/45-51\">",
"     45-51",
"    </a>",
"    ]. The association between the myelitis and the virus is not always clear. In some cases, these may represent a postinfectious transverse myelitis. In others, a positive polymerase chain reaction (PCR) test in the CSF suggests that the myelitis is directly related to the viral infection. These patients are often treated with antiviral agents and corticosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     AIDS myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human immunodeficiency virus (HIV) infection produces a vacuolar myelopathy, which is found in up to half of patients with AIDS at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/36,52\">",
"     36,52",
"    </a>",
"    ]. However, clinical manifestations occur when the pathology is advanced, and only about one-fourth of patients demonstrating vacuolar myelopathy at autopsy have symptoms during life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/53\">",
"     53",
"    </a>",
"    ]. AIDS myelopathy most often occurs in late stages of AIDS; most patients die within six months of developing symptoms of myelopathy. HIV-related dementia is present in more than half of patients and, with other disease complications, may obscure the myelopathy.",
"   </p>",
"   <p>",
"    In typical cases, a slowly progressive spastic paraparesis is accompanied by loss of vibration and position sense and urinary frequency, urgency, and incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/28\">",
"     28",
"    </a>",
"    ]. Upper-extremity function is usually normal. MRI of the spine is usually normal. CSF examination may show nonspecific abnormalities, such as protein elevation. Abnormal sensory evoked potentials may precede clinical symptoms of myelopathy. Aggressive antiretroviral therapy can lead to improvement of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/54\">",
"     54",
"    </a>",
"    ]. In one case series, the use of intravenous immunoglobulin appeared to be associated with neurologic improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of vacuolar myelopathy is unknown, but may be related to abnormal transmethylation mechanisms induced by the virus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cytokines. In one series of 16 patients, there was no correlation between the viral load in the CSF and the presence or severity of myelopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/56\">",
"     56",
"    </a>",
"    ]. Pathological descriptions include demyelination of the dorsal columns and the dorsal half of the lateral columns, with prominent vacuoles within the myelin sheaths. This pathologic appearance is similar to the changes seen in the subacute combined degeneration of the cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     HTLV-1 myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human T-cell lymphotropic virus type I (HTLV-1) causes a progressive neurologic disease, which is called either HTLV-1-associated myelopathy (HAM) or tropical spastic paraparesis (TSP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. This disorder is endemic in southern Japan, the Caribbean, South America, the Melanesian islands, Papua New Guinea, the Middle East, and central and southern Africa, with seroprevalences as high as 30 percent in southern Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. In contrast, it is quite rare in the United States and Europe. It is more common in women than men.",
"   </p>",
"   <p>",
"    Primarily involving the thoracic cord,",
"    <span class=\"nowrap\">",
"     HAM/TSP",
"    </span>",
"    is characterized by a slowly progressive spastic paraparesis and urinary disturbance. Pathologic studies demonstrate inflammation of the lateral corticospinal, spinocerebellar, and spinothalamic tracts, with relative sparing of the posterior columns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/62\">",
"     62",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     HAM/TSP",
"    </span>",
"    has also been associated with other nervous system pathology that results in less frequent symptoms, suggesting cerebral, cerebellar, cranial nerve, and peripheral nerve involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/57,61\">",
"     57,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI of the spinal cord may show atrophy of the cervical or thoracic cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/58\">",
"     58",
"    </a>",
"    ]. A brain MRI often shows subcortical, periventricular white matter lesions. CSF examination reveals a mild lymphocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated protein concentration in some patients. Anti-HTLV-I antibodies are detected in the CSF with a high",
"    <span class=\"nowrap\">",
"     CSF/serum",
"    </span>",
"    ratio. The virus can be cultured from CSF lymphocytes and proviral DNA detected by PCR.",
"   </p>",
"   <p>",
"    In general, neurologic deficits continue to progress slowly; steroids and other immunomodulatory treatment may slow progression, but this is not proven. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40808?source=see_link\">",
"     \"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5897?source=see_link\">",
"     \"Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tabes dorsalis is a form of tertiary neurosyphilis in which the dorsal or posterior columns of the spinal cord are primarily affected. Patients present with a sensory ataxia and lancinating pains reflecting dorsal column and dorsal nerve root involvement. CSF examination may be normal or demonstrate elevated protein level, lymphocytosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a reactive VDRL. Antibiotic treatment may reverse symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=see_link&amp;anchor=H13#H13\">",
"     \"Neurosyphilis\", section on 'Tabes dorsalis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Syphilitic meningomyelitis and meningovascular myelitis represent an earlier form of syphilis infection in which focal inflammation of the meninges secondarily affects the adjacent spinal cord",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the anterior spinal artery. In the former situation, a subacute progressive myelopathy develops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/63\">",
"     63",
"    </a>",
"    ]. In the latter, the clinical presentation may be one of a spinal cord infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=see_link&amp;anchor=H10#H10\">",
"     \"Neurosyphilis\", section on 'Meningovascular syphilis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40631?source=see_link\">",
"     \"Spinal cord infarction: Vascular anatomy and etiologies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis can produce a myelopathy by different mechanisms. Infection of the vertebral body leads to tuberculous spondylitis or Pott's disease, which can lead to secondary cord compression. These patients present with back pain over the affected vertebra, low grade fever, and weight loss, followed by a secondary compressive myelopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/64\">",
"     64",
"    </a>",
"    ]. Tuberculomas within the intramedullary, intradural, and extradural space can also produce myelopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/49/37656?source=see_link\">",
"     \"Skeletal tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28713?source=see_link\">",
"     \"Central nervous system tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Parasite infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parasites Schistosoma mansoni and Schistosoma haematobium typically infect the spinal cord, producing rapidly progressing symptoms of transverse myelitis, including lower limb pain, weakness, and bowel and bladder dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. The lower thoracic region of the spinal cord is most frequently involved, followed by the lumbar and sacral regions. Spinal cord involvement can lead to permanent paralysis. CSF evaluation reveals pleocytosis and elevated protein; eosinophilia occurs in almost half of patients. MRI demonstrates signal change and swelling within the cord. Most patients are treated with glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    and achieve at least partial recovery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14807?source=see_link\">",
"     \"Treatment and prevention of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cysticercosis has been reported to cause a cyst within the spinal cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial meningitis may be complicated by a myelopathy due to formation of an epidural abscess, myelitis, or vasculitic infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/64,70,71\">",
"     64,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lyme disease rarely affects the spinal cord. However, cases have been described in which clinical and MRI features resembling acute transverse myelitis have been attributed to Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. CSF in these cases typically demonstrates a lymphocytic pleocytosis and elevated protein. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     VASCULAR DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Spinal cord infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infarction of the spinal cord is rare compared with cerebral infarction. Spinal cord infarction is most frequently caused by surgical procedures and pathologies affecting the aorta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/74\">",
"     74",
"    </a>",
"    ]. Other causes of spinal cord infarction are diverse and include any etiology that also produces brain infarction (eg, atherosclerosis, embolism, and hypercoagulable and vasculitic disorders) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/74-77\">",
"     74-77",
"    </a>",
"    ]. Spinal cord infarction can also occur in the setting of severe systemic hypotension or cardiac arrest.",
"   </p>",
"   <p>",
"    Symptoms are consistent with the functional loss within the anterior spinal artery territory and include paralysis, loss of bladder function, and loss of pain and temperature sensation below the level of the lesion. Position and vibratory sensation are spared. The onset of symptoms is sudden and is frequently associated with back pain.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) will demonstrate a T2-signal change consistent with cord ischemia, but may be normal in the first 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Diffusion-weighted imaging (DWI) is more sensitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Cerebrospinal fluid (CSF) protein level may be elevated but pleocytosis is rare.",
"   </p>",
"   <p>",
"    Less than half of patients show substantial motor recovery following spinal cord infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/74,83\">",
"     74,83",
"    </a>",
"    ]. Treatment is generally supportive and focused on the underlying aortic pathology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    secondary stroke prevention.",
"   </p>",
"   <p>",
"    Spinal cord infarction is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40631?source=see_link\">",
"     \"Spinal cord infarction: Vascular anatomy and etiologies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23333?source=see_link\">",
"     \"Spinal cord infarction: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Vascular malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular malformations of the spinal cord are classified into types according to their location and vascular pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dural arteriovenous fistula is the most common type, making up about 70 percent of all lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/86\">",
"     86",
"    </a>",
"    ]. These exist on the dural surface, and drain intradurally by retrograde flow through a single medullary vein to the anterior or posterior median vein, resulting in engorgement of the coronal venous plexus. They usually present after the fifth decade of life and are more common in men. The most common clinical presentation is that of progressive, often step-wise myeloradiculopathy, probably related to venous hypertension. Some patients present with neurogenic claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/87\">",
"     87",
"    </a>",
"    ]. Symptoms may initially fluctuate, but eventually a permanent and progressive paraparesis with sensory disturbances and sphincter dysfunction occur.",
"   </p>",
"   <p>",
"    MRI with contrast-enhanced MR angiography (MRA) can identify a dural arteriovenous fistula, but has imperfect sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/87-91\">",
"     87-91",
"    </a>",
"    ]. The most common finding is a nonspecific hyperintense signal lesion on T2-weighted images. The more specific findings of intradural flow voids on T2-weighted images,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serpentine enhancement on MRA and T1 images, are seen in 85 to 90 percent of patients. If",
"    <span class=\"nowrap\">",
"     MRI/MRA",
"    </span>",
"    is negative or cannot be performed, myelography with supine and prone images, may demonstrate the serpentine vessels within the intradural space. When positive, MRA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myelography can help guide the performance of the spinal angiogram, which remains the gold standard test, and is required prior to therapeutic intervention. Spinal angiography can be a difficult diagnostic procedure in this setting, often requiring multiple injections of segmental arteries in order to identify the feeding artery, especially when MRA does not provide specific guiding information. However, at least one observational study found that in experienced hands, the complication rate is low (1 to 2 percent) and did not (at least in this series) involve any neurologic morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/92\">",
"     92",
"    </a>",
"    ]. Occlusion of the fistula by surgery or endovascular embolization can be helpful in stabilizing, even ameliorating, the neurologic deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/91,93,94\">",
"     91,93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intramedullary spinal arteriovenous malformations (AVMs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/95,96\">",
"     95,96",
"    </a>",
"    ] are supplied by medullary arteries and drain through medullary veins. The mean age at clinical presentation is the mid-20s, but close to 20 percent of the lesions are diagnosed in children under 16 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/95\">",
"     95",
"    </a>",
"    ]. A myelopathy is produced by the mass effect of the lesion or by ischemia or hemorrhage into the cord. Some patients present instead with subarachnoid hemorrhage. MRI is sensitive for intramedullary AVM, showing a cluster of low intensity signal foci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/85\">",
"     85",
"    </a>",
"    ]. Contrast-enhanced MRA also helps localize the nidus and identify arterial supply and venous drainage. These lesions are treated by endovascular occlusion, surgical resection, or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Spinal epidural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal epidural hematoma can complicate procedures that involve a spinal dural puncture, usually in patients with thrombocytopenia or bleeding diathesis, including anticoagulant therapy. Rarely, this occurs spontaneously; a predisposition to bleeding is a risk factor in these patients as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. Some occur in the setting of minor trauma.",
"   </p>",
"   <p>",
"    Patients typically present with local",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radicular pain, followed by loss of sensory, motor, and bladder and bowel function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. The source of bleeding is usually venous rather than arterial and symptoms typically present over days, although more abrupt presentations are also described.",
"   </p>",
"   <p>",
"    MRI is a sensitive imaging modality for these lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/99,101\">",
"     99,101",
"    </a>",
"    ]. MRI findings vary according to the age of the clot. In the first 24 hours the hematoma is usually isointense on T1- and hyperintense on T2-weighted images, after 24 hours, it becomes mostly hyperintense on T1 and on T2.",
"   </p>",
"   <p>",
"    The appropriate treatment for patients with significant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progressing neurologic deficits is prompt surgical intervention, usually a laminectomy, and evacuation of the blood. Timely decompression of the hematoma is essential to avoid permanent loss of neurologic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. Many individuals with minor, stable neurologic deficits can be managed by observation and have a good prognosis for complete recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/98,100\">",
"     98,100",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TOXIC, METABOLIC DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Subacute combined degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency in vitamin B12 (cyanocobalamin) leads to degeneration of the dorsal and lateral white matter of the spinal cord, producing a slowly progressive weakness, sensory ataxia, and paresthesias, and ultimately spasticity, paraplegia, and incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/104\">",
"     104",
"    </a>",
"    ]. Not all patients with neurologic abnormalities will have anemia or macrocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/105\">",
"     105",
"    </a>",
"    ]. Supplemental treatment with vitamin B12 can stop progression and will produce neurologic improvement in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link&amp;anchor=H2126391#H2126391\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    abuse can also lead to subacute combined degeneration, by inactivation of vitamin B12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33753?source=see_link\">",
"     \"Inhalant abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20816123\">",
"    <span class=\"h2\">",
"     Copper deficiency myeloneuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A syndrome similar to the subacute combined degeneration of vitamin B12 deficiency can occur with acquired copper deficiency, which may be the result of gastrointestional surgery, excessive zinc ingestion (eg, overuse of denture cream), and other causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/110-112\">",
"     110-112",
"    </a>",
"    ]. Most patients also have hematologic abnormalities. Treatment can prevent progression, but patients with significant neurologic deficits at presentation often remain disabled. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11880?source=see_link\">",
"     \"Copper deficiency myeloneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Radiation myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelopathy is a serious complication of radiation therapy to the spinal cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. White matter tracts in the lateral aspects of the cord are preferentially affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Two distinct clinical presentations are described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A transient myelopathy occurring two to six months after irradiation is usually mild and resolves spontaneously over several months.",
"     </li>",
"     <li>",
"      A late progressive myelopathy begins 6 to 12 months after irradiation. This begins insidiously and generally progresses inexorably, although some cases stabilize. Magnetic resonance imaging (MRI) is important to exclude other etiologies and will typically show hyperintensity on T2 and FLAIR sequences. A high radiation dose is a risk factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/117\">",
"       117",
"      </a>",
"      ]. Fractionation size, concomitant chemotherapy, and other comorbidities may play a role. There is no effective treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7190?source=see_link\">",
"     \"Complications of spinal cord irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Electrical injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;High voltage electrical injury can be associated with a variety of neurologic complications, including spinal cord injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4410?source=see_link\">",
"     \"Environmental electrical injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different syndromes have been described:",
"   </p>",
"   <p>",
"    A transient flaccid paralysis, called keraunoparalysis, is apparent immediately following the injury, affects the legs more than the arms, and typically resolves within the first 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. This is most often described in association with lightning strike. Peripheral vasoconstriction and sensory disturbances are commonly associated. The pathophysiology is uncertain.",
"   </p>",
"   <p>",
"    Other patients with electrical injury develop a more enduring and sometimes permanent spinal cord injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/120-123\">",
"     120-123",
"    </a>",
"    ]. In this situation, clinical signs of myelopathy may be present at the time of injury, or may develop after several days or weeks. Motor deficits are more prominent than sensory findings. Bladder and other sphincter dysfunction can occur. Spine MRI is typically normal. The clinical course and prognosis are not well characterized. Direct heat and electrical injury to neural elements, as well as a delayed microvascular disease are proposed mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hepatic myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive myelopathy is a rare neurologic complication of chronic liver disease with portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/124-127\">",
"     124-127",
"    </a>",
"    ]. The myelopathy is predominantly or entirely motor in manifestation, reflected as a spastic paraparesis that progresses over months to paraplegia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/128\">",
"     128",
"    </a>",
"    ]. Deficits are limited to the lower extremities; sensory and bladder function is often unaffected. MRI and cerebrospinal fluid (CSF) studies are normal. Neuropathological studies have demonstrated demyelination of the lateral corticospinal tracts with various degrees of axonal loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to hepatic encephalopathy, ammonia-lowering treatments have little or no effect on the myelopathy, but patients with early manifestations of spinal cord impairment may improve with liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Decompression sickness myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impairment of spinal cord function can be a manifestation of decompression sickness, a complication of deep sea diving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/129-133\">",
"     129-133",
"    </a>",
"    ]. Symptoms usually develop during or immediately after ascent but may be delayed for several hours or a few days. The thoracic cord is most commonly involved, producing paraparesis of varying severity and a sensory level in the mid or low thoracic region. Lesions at higher spinal cord levels producing quadriplegia have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early therapeutic recompression frequently reverses symptoms and signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/130\">",
"     130",
"    </a>",
"    ]. Residual corticospinal and minor sensory signs may remain for months or indefinitely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/133\">",
"     133",
"    </a>",
"    ]. Both MRI and pathologic studies have shown multifocal white matter degeneration in the posterior and lateral columns of the spinal cord with secondary ascending and descending tract degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/127,132\">",
"     127,132",
"    </a>",
"    ]. Gaseous occlusion of venous plexi within the spinal cord is one postulated mechanism of injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4633?source=see_link&amp;anchor=H18#H18\">",
"     \"Complications of scuba diving\", section on 'Type II decompression sickness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Lathyrism and konzo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two disorders of spastic paraparesis have been described, which occur in association with increased dietary intake of food plants with neurotoxic potential, as occurs in certain geographic regions during times of famine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/134,135\">",
"     134,135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurolathyrism is associated with prolonged consumption of the grass or chickling pea (Lathyrus sativus) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/136\">",
"       136",
"      </a>",
"      ]. Exposed persons develop a slowly developing spastic paraparesis with cramps, paresthesias, and numbness, accompanied by bladder symptoms and impotence. Some patients have tremors and other involuntary movements in their arms. Pathologic studies have demonstrated a loss of myelinated fibers in the corticospinal and spinocerebellar tracts. The toxin appears to be the neuroexcitatory amino acid, beta-N-oxalylaminoalanine. There is no treatment.",
"     </li>",
"     <li>",
"      Konzo, a disorder characterized by acute spastic paraparesis or quadriparesis, is linked to high exposure to cyanogenic compounds in diets containing insufficiently processed bitter cassava (Manihot esculenta) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/137,138\">",
"       137,138",
"      </a>",
"      ]. This disorder is less well characterized than lathyrism, and it may reflect a disorder of intracranial rather than intraspinal motor pathways.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both benign and malignant tumors can produce a myelopathy as a result of external compression or intramedullary growth.",
"   </p>",
"   <p>",
"    The most common syndrome is that of extradural spinal cord compression, as produced by metastases to the extradural space. Patients present with a progressive weakness below the level of the lesion with accompanying sensory loss and bladder dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/139\">",
"     139",
"    </a>",
"    ]. Pain at the site of involvement is typical. Progression to paraplegia can occur abruptly, as a result of vascular compression. Because the prognosis for neurologic recovery depends on the severity of the deficit at the time of intervention (high-dose corticosteroids with radiation therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical decompression), diagnostic evaluation (with gadolinium-enhanced spinal MRI) must proceed promptly when this diagnosis is considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/140\">",
"     140",
"    </a>",
"    ]. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=see_link\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intramedullary spinal cord tumors are typically primary central nervous system tumors (ependymoma, astrocytoma); metastases are less likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/141,142\">",
"     141,142",
"    </a>",
"    ]. These produce a progressive myelopathy, often with central cord features. MRI with gadolinium will show the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/143\">",
"     143",
"    </a>",
"    ]; biopsy with histologic examination is usually required for diagnosis. Because of their intramedullary location, management of these lesions is difficult. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/63/7161?source=see_link\">",
"     \"Spinal cord tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myelopathy can also occur as a complication of radiation therapy (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Radiation myelopathy'",
"    </a>",
"    above), as a complication of intrathecal chemotherapy, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link&amp;anchor=H5#H5\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Transverse myelopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link&amp;anchor=H29#H29\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Intrathecal cytarabine'",
"    </a>",
"    ), and as a paraneoplastic syndrome (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Paraneoplastic syndromes'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6583?source=see_link\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INHERITED AND DEGENERATIVE CONDITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Amyotrophic lateral sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that produces progressive weakness, usually with mixed upper and motor neuron signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/144,145\">",
"     144,145",
"    </a>",
"    ]. Symptoms begin insidiously in older adults (usually &gt;60 years) and progress inexorably. In typical patients, there is asymmetric limb weakness with a mixture of upper and lower motor neuron features. Sensory and sphincter disturbances are usually absent. Magnetic resonance imaging (MRI) is normal. Electromyography typically shows denervation in clinically affected muscles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unusual variants of ALS with atypical symptoms can present a diagnostic challenge. Primary lateral sclerosis is a rare variant of ALS with primarily upper motor neuron features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/146\">",
"     146",
"    </a>",
"    ]. Muscle stiffness leading to overt and progressive spasticity without associated muscle weakness or atrophy typifies the disorder. In about two-thirds of patients, there is an ascending pattern with spasticity spreading in a rather stereotyped fashion from the legs to the arms and finally to involve the bulbar musculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/147\">",
"     147",
"    </a>",
"    ]. Without positive test findings, this is a diagnosis of exclusion. There is no treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Primary lateral sclerosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One familial form of ALS, the recessively inherited D90A mutation, can also present with atypical features, including a long pre-paretic phase of lower extremity discomfort, followed by a slowly ascending asymmetric paresis that is often accompanied by bladder symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/148-151\">",
"     148-151",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16138?source=see_link\">",
"     \"Familial amyotrophic lateral sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Hereditary spastic paraplegias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary spastic paraplegia (HSP) is a large group of inherited neurologic disorders, in which the prominent feature is a progressive spastic paraparesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/152\">",
"     152",
"    </a>",
"    ]. HSP is classified according to the mode of inheritance, the genetic locus when known, and whether the spastic paraplegia syndrome occurs alone or is accompanied by additional neurologic or systemic abnormalities (\"pure\" versus \"complicated\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/153-157\">",
"     153-157",
"    </a>",
"    ]. There have been no recent epidemiological studies, but previously the incidence has been reported to be between 1 in 10,000 and 1 in 100,000.",
"   </p>",
"   <p>",
"    Genetically diverse, with at least 28 genetic loci for HSP identified, the final common pathway for these disorders is a degeneration of the corticospinal tracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/153\">",
"     153",
"    </a>",
"    ]. Studies in animal models suggest that in individual disorders, disruption in axonal transport, cytoskeleton regulation, mitochondrial function, myelin maintenance and assembly, or neuronal migration may be the primary functional derangement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/155\">",
"     155",
"    </a>",
"    ]. Inheritance is usually autosomal dominant, but recessive and X-linked variants are known. One X-linked variant related to Pelizaeus-Merzbacher disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/9/13465?source=see_link&amp;anchor=H13#H13\">",
"     \"Pelizaeus-Merzbacher disease\", section on 'X-linked spastic paraplegia type 2'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/9/13465?source=see_link&amp;anchor=H24#H24\">",
"     \"Pelizaeus-Merzbacher disease\", section on 'Hereditary spastic paraplegia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical patient with pure HSP will have a slowly progressive spastic paraparesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/153\">",
"     153",
"    </a>",
"    ]. The age of onset can vary from infancy to the eighth decade. The first symptoms are often gait disturbance or urinary urgency. Examination reveals spasticity, hyperreflexia, extensor plantar responses, and impaired vibration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    joint position sense. Weakness may be demonstrated but is rarely the major cause of disability. Upper limb involvement is generally limited to hyperreflexia.",
"   </p>",
"   <p>",
"    HSP is a clinical diagnosis, based in large part on the family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/153\">",
"     153",
"    </a>",
"    ]. MRI may be normal or may show atrophy in the spinal cord. Thinning of the corpus callosum on brain MRI is seen in half of patients with the autosomal recessive form of HSP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/158\">",
"     158",
"    </a>",
"    ]. Otherwise, the diagnosis is based on careful exclusion of other etiologies. Treatment for HSP is limited to symptomatic management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Adrenoleukodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenomyeloneuropathy, a variant of adrenoleukodystrophy, an x-linked recessive disorder, is characterized by a slowly progressive spastic paraparesis and mild polyneuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/159,160\">",
"     159,160",
"    </a>",
"    ]. As opposed to the more common and severe phenotype of adrenoleukodystrophy, adrenomyeloneuropathy generally presents in adult men or in female carriers of the mutation. Sensory and sphincter disturbances are typically absent. There may be mild adrenal insufficiency. MRI is typically normal. In the absence of a family history, the finding of a neuropathy on electrophysiologic testing may be a clue to the disorder. The diagnosis is made by the finding of increased very long chain fatty acids in plasma, red blood cells, or cultured skin fibroblasts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33673?source=see_link\">",
"     \"Adrenoleukodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12408?source=see_link&amp;anchor=H2#H2\">",
"     \"Unusual causes of adrenal insufficiency\", section on 'Adrenoleukodystrophy and adrenomyeloneuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Friedreich ataxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Friedreich ataxia is an autosomal recessive degenerative disorder of uncertain pathogenesis that typically presents in adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/161\">",
"     161",
"    </a>",
"    ]. The neuropathologic changes in Friedreich ataxia include degeneration of the posterior columns and the spinocerebellar tracts of the spinal cord and loss of the larger sensory cells of the dorsal root ganglia. These findings correspond to the clinical manifestations of progressive ataxia of all four limbs and gait, weakness, absent reflexes with extensor plantar responses, loss of position and vibration sense, and sparing of pain and temperature. Cardiomyopathy and diabetes mellitus are part of the syndrome. Patients with late-onset disease are more likely to have retained reflexes, spasticity, and no cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/162\">",
"     162",
"    </a>",
"    ]. MRI may show atrophy of the cervical cord. Disease severity and rate of progression are highly variable. There is no treatment. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15432?source=see_link\">",
"     \"Friedreich ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     OTHERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Syringomyelia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syringomyelia is a fluid-filled, gliosis-lined cavity within the spinal cord. Most lesions are between C2 and T9; however, they can descend further down or extend upward into the brainstem (syringobulbia). A syrinx can represent a focal dilation of the central canal, or it may lie separately, within the spinal cord parenchyma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/163\">",
"     163",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Syringomyelia most commonly occurs in the setting of the Arnold Chiari malformation Type 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/164\">",
"     164",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26697?source=see_link\">",
"     \"Chiari malformations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of syringomyelia are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/163-167\">",
"     163-167",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other congenital malformations (eg, Klippel-Feil syndrome, and tethered spinal cord) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18842?source=see_link&amp;anchor=H789932#H789932\">",
"       \"Evaluation of neck stiffness in children\", section on 'Congenital'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postinfectious",
"     </li>",
"     <li>",
"      Postinflammatory (transverse myelitis and multiple sclerosis)",
"     </li>",
"     <li>",
"      Spinal neoplasms (especially ependymoma and hemangioblastoma) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/63/7161?source=see_link\">",
"       \"Spinal cord tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Posttraumatic (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=see_link&amp;anchor=H28#H28\">",
"       \"Chronic complications of spinal cord injury\", section on 'Syringomyelia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A syrinx can be asymptomatic and discovered incidentally on spinal cord imaging. Other patients present with progressive central cord deficits that can include a prominent central pain syndrome in a segmental distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/168\">",
"     168",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) will typically identify the intramedullary cavity; gadolinium administration will increase the sensitivity of finding an associated tumor. Surgical decompression with fenestration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shunt placement is recommended for patients with neurologic deterioration or intractable central pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/166-168\">",
"     166-168",
"    </a>",
"    ]. Neurologic deficits usually stabilize after intervention and sometimes improve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Cervical spondylotic myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many case series, cervical spondylotic myelopathy is the most common cause of myelopathy, particularly in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/1\">",
"     1",
"    </a>",
"    ]. Degenerative changes in the vertebral bodies, discs, and connecting ligaments encroach on the cervical canal, producing a progressive myelopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/169\">",
"     169",
"    </a>",
"    ]. Symptoms begin insidiously, usually with a spastic gait. Sensory loss, muscle weakness, and atrophy in the hands also cause functional impairment over time. Some patients may develop or present with an acute myelopathy characterized by a central cord syndrome, often in the setting of mild neck trauma.",
"   </p>",
"   <p>",
"    The diagnosis is made by correlating clinical features with evidence of cervical spondylosis and cord compression on MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/42/32426/abstract/170\">",
"     170",
"    </a>",
"    ]. Treatment options include cervical immobilization and surgical decompression. When and if to operate remains controversial. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27944?source=see_link\">",
"     \"Cervical spondylotic myelopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/53/27475?source=see_link\">",
"       \"Patient information: Paraplegia and quadriplegia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/57/3986?source=see_link\">",
"       \"Patient information: Friedreich ataxia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologies that affect the spinal cord are diverse. Common etiologies of myelopathy include autoimmune, infectious, neoplastic, vascular, and hereditary-degenerative diseases. The neurologic examination will characterize the deficits as to the spinal cord syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spinal cord syndrome along with the clinical setting and course of presentation with the findings on a neuroimaging study (usually magnetic resonance imaging) will identify the likely pathogenesis in most cases (",
"    <a class=\"graphic graphic_table graphicRef50336 \" href=\"mobipreview.htm?6/0/6157\">",
"     table 1",
"    </a>",
"    ). (See individual topic reviews above).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/1\">",
"      Moore AP, Blumhardt LD. A prospective survey of the causes of non-traumatic spastic paraparesis and tetraparesis in 585 patients. Spinal Cord 1997; 35:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/2\">",
"      Brinar VV, Habek M, Brinar M, et al. The differential diagnosis of acute transverse myelitis. Clin Neurol Neurosurg 2006; 108:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/3\">",
"      Budka H. Neuropathology of myelitis, myelopathy, and spinal infections in AIDS. Neuroimaging Clin N Am 1997; 7:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/4\">",
"      Cree BA, Wingerchuk DM. Acute transverse myelitis: is the \"idiopathic\" form vanishing? Neurology 2005; 65:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/5\">",
"      Jeffery DR, Mandler RN, Davis LE. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol 1993; 50:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/6\">",
"      de Seze J, Lanctin C, Lebrun C, et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005; 65:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/7\">",
"      Kaplin AI, Krishnan C, Deshpande DM, et al. Diagnosis and management of acute myelopathies. Neurologist 2005; 11:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/8\">",
"      Pidcock FS, Krishnan C, Crawford TO, et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007; 68:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/9\">",
"      Thorpe JW, Kidd D, Moseley IF, et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 1996; 119 ( Pt 3):709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/10\">",
"      Lehnhardt FG, Impekoven P, Rubbert A, et al. Recurrent longitudinal myelitis as primary manifestation of SLE. Neurology 2004; 63:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/11\">",
"      Krishnan AV, Halmagyi GM. Acute transverse myelitis in SLE. Neurology 2004; 62:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/12\">",
"      Mok CC, Lau CS. Transverse myelopathy complicating mixed connective tissue disease. Clin Neurol Neurosurg 1995; 97:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/13\">",
"      Anantharaju A, Baluch M, Van Thiel DH. Transverse myelitis occurring in association with primary biliary cirrhosis and Sjogren's syndrome. Dig Dis Sci 2003; 48:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/14\">",
"      Rabadi MH, Kundi S, Brett D, Padmanabhan R. Neurological pictures. Primary Sj&ouml;gren syndrome presenting as neuromyelitis optica. J Neurol Neurosurg Psychiatry 2010; 81:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/15\">",
"      Torabi AM, Patel RK, Wolfe GI, et al. Transverse myelitis in systemic sclerosis. Arch Neurol 2004; 61:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/16\">",
"      Oh DH, Jun JB, Kim HT, et al. Transverse myelitis in a patient with long-standing ankylosing spondylitis. Clin Exp Rheumatol 2001; 19:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/17\">",
"      Harzheim M, Schlegel U, Urbach H, et al. Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients. J Neurol Sci 2004; 217:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/18\">",
"      Knebusch M, Strassburg HM, Reiners K. Acute transverse myelitis in childhood: nine cases and review of the literature. Dev Med Child Neurol 1998; 40:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/19\">",
"      Bakshi R, Kinkel PR, Mechtler LL, et al. Magnetic resonance imaging findings in 22 cases of myelitis: comparison between patients with and without multiple sclerosis. Eur J Neurol 1998; 5:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/20\">",
"      Choi KH, Lee KS, Chung SO, et al. Idiopathic transverse myelitis: MR characteristics. AJNR Am J Neuroradiol 1996; 17:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/21\">",
"      Cordonnier C, de Seze J, Breteau G, et al. Prospective study of patients presenting with acute partial transverse myelopathy. J Neurol 2003; 250:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/22\">",
"      Defresne P, Hollenberg H, Husson B, et al. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol 2003; 18:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/23\">",
"      Bruna J, Mart&iacute;nez-Y&eacute;lamos S, Mart&iacute;nez-Y&eacute;lamos A, et al. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler 2006; 12:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/24\">",
"      Seifert T, Enzinger C, Ropele S, et al. Relapsing acute transverse myelitis: a specific entity. Eur J Neurol 2005; 12:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/25\">",
"      Kim KK. Idiopathic recurrent transverse myelitis. Arch Neurol 2003; 60:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/26\">",
"      Greenberg BM, Thomas KP, Krishnan C, et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007; 68:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/27\">",
"      Scott TF, Bhagavatula K, Snyder PJ, Chieffe C. Transverse myelitis. Comparison with spinal cord presentations of multiple sclerosis. Neurology 1998; 50:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/28\">",
"      Ford B, Tampieri D, Francis G. Long-term follow-up of acute partial transverse myelopathy. Neurology 1992; 42:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/29\">",
"      Kumar N, Frohman EM. Spinal neurosarcoidosis mimicking an idiopathic inflammatory demyelinating syndrome. Arch Neurol 2004; 61:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/30\">",
"      Junger SS, Stern BJ, Levine SR, et al. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology 1993; 43:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/31\">",
"      Saleh S, Saw C, Marzouk K, Sharma O. Sarcoidosis of the spinal cord: literature review and report of eight cases. J Natl Med Assoc 2006; 98:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/32\">",
"      Rosenfeld MR, Posner JB. Paraneoplastic motor neuron disease. Adv Neurol 1991; 56:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/33\">",
"      Ojeda VJ. Necrotizing myelopathy associated with malignancy. A clinicopathologic study of two cases and literature review. Cancer 1984; 53:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/34\">",
"      Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/35\">",
"      Darouiche RO. Spinal epidural abscess. N Engl J Med 2006; 355:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/36\">",
"      Woolsey RM, McGarry JD. AIDS related spinal cord syndromes. J Am Paraplegia Soc 1989; 12:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/37\">",
"      Solomon T, Willison H. Infectious causes of acute flaccid paralysis. Curr Opin Infect Dis 2003; 16:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/38\">",
"      Chen CY, Chang YC, Huang CC, et al. Acute flaccid paralysis in infants and young children with enterovirus 71 infection: MR imaging findings and clinical correlates. AJNR Am J Neuroradiol 2001; 22:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/39\">",
"      John TJ. Spinal cord disease in West Nile virus infection. N Engl J Med 2003; 348:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/40\">",
"      Kelley TW, Prayson RA, Isada CM. Spinal cord disease in West Nile virus infection. N Engl J Med 2003; 348:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/41\">",
"      Jeha LE, Sila CA, Lederman RJ, et al. West Nile virus infection: a new acute paralytic illness. Neurology 2003; 61:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/42\">",
"      Kraushaar G, Patel R, Stoneham GW. West Nile Virus: a case report with flaccid paralysis and cervical spinal cord: MR imaging findings. AJNR Am J Neuroradiol 2005; 26:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/43\">",
"      Cao NJ, Ranganathan C, Kupsky WJ, Li J. Recovery and prognosticators of paralysis in West Nile virus infection. J Neurol Sci 2005; 236:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/44\">",
"      Arya SC, Agarwal N. Spinal cord neuropathology in human West Nile virus infection. Arch Pathol Lab Med 2004; 128:1210; author reply 1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/45\">",
"      Fux CA, Pfister S, Nohl F, Zimmerli S. Cytomegalovirus-associated acute transverse myelitis in immunocompetent adults. Clin Microbiol Infect 2003; 9:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/46\">",
"      Nakajima H, Furutama D, Kimura F, et al. Herpes simplex virus myelitis: clinical manifestations and diagnosis by the polymerase chain reaction method. Eur Neurol 1998; 39:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/47\">",
"      Shyu WC, Lin JC, Chang BC, et al. Recurrent ascending myelitis: an unusual presentation of herpes simplex virus type 1 infection. Ann Neurol 1993; 34:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/48\">",
"      Kincaid O, Lipton HL. Viral myelitis: an update. Curr Neurol Neurosci Rep 2006; 6:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/49\">",
"      Aktipi KM, Ravaglia S, Ceroni M, et al. Severe recurrent myelitis in patients with hepatitis C virus infection. Neurology 2007; 68:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/50\">",
"      Orme HT, Smith AG, Nagel MA, et al. VZV spinal cord infarction identified by diffusion-weighted MRI (DWI). Neurology 2007; 69:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/51\">",
"      Young-Barbee C, Hall DA, LoPresti JJ, et al. Brown-S&eacute;quard syndrome after herpes zoster. Neurology 2009; 72:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/52\">",
"      Di Rocco A. Diseases of the spinal cord in human immunodeficiency virus infection. Semin Neurol 1999; 19:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/53\">",
"      Dal Pan GJ, Glass JD, McArthur JC. Clinicopathologic correlations of HIV-1-associated vacuolar myelopathy: an autopsy-based case-control study. Neurology 1994; 44:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/54\">",
"      Staudinger R, Henry K. Remission of HIV myelopathy after highly active antiretroviral therapy. Neurology 2000; 54:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/55\">",
"      Cikurel K, Schiff L, Simpson DM. Pilot study of intravenous immunoglobulin in HIV-associated myelopathy. AIDS Patient Care STDS 2009; 23:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/56\">",
"      Geraci A, Di Rocco A, Liu M, et al. AIDS myelopathy is not associated with elevated HIV viral load in cerebrospinal fluid. Neurology 2000; 55:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/57\">",
"      Grindstaff P, Gruener G. The peripheral nervous system complications of HTLV-1 myelopathy (HAM/TSP) syndromes. Semin Neurol 2005; 25:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/58\">",
"      Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet 1999; 353:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/59\">",
"      Oger J, Dekaban G. HTLV-I associated myelopathy: a case of viral-induced auto-immunity. Autoimmunity 1995; 21:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/60\">",
"      Oger JJ, Werker DH, Foti DJ, Dekaban GA. HTLV-I associated myelopathy: an endemic disease of Canadian aboriginals of the Northwest Pacific coast? Can J Neurol Sci 1993; 20:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/61\">",
"      Leite AC, Mendon&ccedil;a GA, Serpa MJ, et al. Neurological manifestations in HTLV-I-infected blood donors. J Neurol Sci 2003; 214:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/62\">",
"      Nagai M, Osame M. Human T-cell lymphotropic virus type I and neurological diseases. J Neurovirol 2003; 9:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/63\">",
"      Chilver-Stainer L, Fischer U, Hauf M, et al. Syphilitic myelitis: rare, nonspecific, but treatable. Neurology 2009; 72:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/64\">",
"      Bal&eacute;riaux DL, Neugroschl C. Spinal and spinal cord infection. Eur Radiol 2004; 14 Suppl 3:E72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/65\">",
"      al-Deeb SM, Yaqub BA, Sharif HS, Motaery KR. Neurotuberculosis: a review. Clin Neurol Neurosurg 1992; 94 Suppl:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/66\">",
"      Bahemuka M, Murungi JH. Tuberculosis of the nervous system. A clinical, radiological and pathological study of 39 consecutive cases in Riyadh, Saudi Arabia. J Neurol Sci 1989; 90:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/67\">",
"      Scrimgeour EM, Gajdusek DC. Involvement of the central nervous system in Schistosoma mansoni and S. haematobium infection. A review. Brain 1985; 108 ( Pt 4):1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/68\">",
"      Ferrari TC. Spinal cord schistosomiasis. A report of 2 cases and review emphasizing clinical aspects. Medicine (Baltimore) 1999; 78:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/69\">",
"      Gon&ccedil;alves FG, Neves PO, Jovem CL, et al. Chronic myelopathy associated to intramedullary cysticercosis. Spine (Phila Pa 1976) 2010; 35:E159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/70\">",
"      Kastenbauer S, Winkler F, Fesl G, et al. Acute severe spinal cord dysfunction in bacterial meningitis in adults: MRI findings suggest extensive myelitis. Arch Neurol 2001; 58:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/71\">",
"      Josephson SA, Pillai DR, Phillips JJ, Chou D. Neurolisteriosis presenting as cervical myelitis in an immunocompetent patient. Neurology 2006; 66:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/72\">",
"      Mantienne C, Albucher JF, Catalaa I, et al. MRI in Lyme disease of the spinal cord. Neuroradiology 2001; 43:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/73\">",
"      Meurs L, Labeye D, Declercq I, et al. Acute transverse myelitis as a main manifestation of early stage II neuroborreliosis in two patients. Eur Neurol 2004; 52:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/74\">",
"      Cheshire WP, Santos CC, Massey EW, Howard JF Jr. Spinal cord infarction: etiology and outcome. Neurology 1996; 47:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/75\">",
"      Faig J, Busse O, Salbeck R. Vertebral body infarction as a confirmatory sign of spinal cord ischemic stroke: report of three cases and review of the literature. Stroke 1998; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/76\">",
"      Fairhead JF, Phillips D, Handa A. Embolic spinal cord infarction as a presentation of abdominal aortic aneurysm. J R Soc Med 2005; 98:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/77\">",
"      Salvarani C, Brown RD Jr, Calamia KT, et al. Primary CNS vasculitis with spinal cord involvement. Neurology 2008; 70:2394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/78\">",
"      Masson C, Pruvo JP, Meder JF, et al. Spinal cord infarction: clinical and magnetic resonance imaging findings and short term outcome. J Neurol Neurosurg Psychiatry 2004; 75:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/79\">",
"      Weidauer S, Nichtweiss M, Lanfermann H, Zanella FE. Spinal cord infarction: MR imaging and clinical features in 16 cases. Neuroradiology 2002; 44:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/80\">",
"      K&uuml;ker W, Weller M, Klose U, et al. Diffusion-weighted MRI of spinal cord infarction--high resolution imaging and time course of diffusion abnormality. J Neurol 2004; 251:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/81\">",
"      Shinoyama M, Takahashi T, Shimizu H, et al. Spinal cord infarction demonstrated by diffusion-weighted magnetic resonance imaging. J Clin Neurosci 2005; 12:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/82\">",
"      Thurnher MM, Bammer R. Diffusion-weighted MR imaging (DWI) in spinal cord ischemia. Neuroradiology 2006; 48:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/83\">",
"      Pelser H, van Gijn J. Spinal infarction. A follow-up study. Stroke 1993; 24:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/84\">",
"      Riche MC, Reizine D, Melki JP, Merland JJ. Classification of spinal cord vascular malformations. Radiat Med 1985; 3:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/85\">",
"      Bemporad JA, Sze GS. MR imaging of spinal cord vascular malformations with an emphasis on the cervical spine. Magn Reson Imaging Clin N Am 2000; 8:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/86\">",
"      Lev N, Maimon S, Rappaport ZH, Melamed E. Spinal dural arteriovenous fistulae--a diagnostic challenge. Isr Med Assoc J 2001; 3:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/87\">",
"      Muralidharan R, Saladino A, Lanzino G, et al. The clinical and radiological presentation of spinal dural arteriovenous fistula. Spine (Phila Pa 1976) 2011; 36:E1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/88\">",
"      Luetmer PH, Lane JI, Gilbertson JR, et al. Preangiographic evaluation of spinal dural arteriovenous fistulas with elliptic centric contrast-enhanced MR Angiography and effect on radiation dose and volume of iodinated contrast material. AJNR Am J Neuroradiol 2005; 26:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/89\">",
"      Saraf-Lavi E, Bowen BC, Quencer RM, et al. Detection of spinal dural arteriovenous fistulae with MR imaging and contrast-enhanced MR angiography: sensitivity, specificity, and prediction of vertebral level. AJNR Am J Neuroradiol 2002; 23:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/90\">",
"      Bemporad JA, Sze G. Magnetic resonance imaging of spinal cord vascular malformations with an emphasis on the cervical spine. Neuroimaging Clin N Am 2001; 11:viii, 111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/91\">",
"      Koch C. Spinal dural arteriovenous fistula. Curr Opin Neurol 2006; 19:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/92\">",
"      Chen J, Gailloud P. Safety of spinal angiography: complication rate analysis in 302 diagnostic angiograms. Neurology 2011; 77:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/93\">",
"      Watson JC, Oldfield EH. The surgical management of spinal dural vascular malformations. Neurosurg Clin N Am 1999; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/94\">",
"      Aghakhani N, Parker F, David P, et al. Curable cause of paraplegia: spinal dural arteriovenous fistulae. Stroke 2008; 39:2756.",
"     </a>",
"    </li>",
"    <li>",
"     Yasargil, MG, Symon, L, Teddy, PG. Arteriovenous malformations of the spinal cord. In: Advances and Technical Standards in Neurosurgery, Symon, L (Ed), Springer, Wien 1984. p.61.",
"    </li>",
"    <li>",
"     Aminoff, MJ. Spinal vascular disease. In: Spinal Cord Disease: Basic Science, Diagnosis and Management, Critchley, E, Eisen, A, (Eds), Springer, London 1992. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/97\">",
"      Zozulya YP, Slin'ko EI, Al-Qashqish II. Spinal arteriovenous malformations: new classification and surgical treatment. Neurosurg Focus 2006; 20:E7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/98\">",
"      Thiele RH, Hage ZA, Surdell DL, et al. Spontaneous spinal epidural hematoma of unknown etiology: case report and literature review. Neurocrit Care 2008; 9:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/99\">",
"      Liu WH, Hsieh CT, Chiang YH, Chen GJ. Spontaneous spinal epidural hematoma of thoracic spine: a rare case report and review of literature. Am J Emerg Med 2008; 26:384.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/100\">",
"      SreeHarsha CK, Rajasekaran S, Dhanasekararaja P. Spontaneous complete recovery of paraplegia caused by epidural hematoma complicating epidural anesthesia: a case report and review of literature. Spinal Cord 2006; 44:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/101\">",
"      Braun P, Kazmi K, Nogu&eacute;s-Mel&eacute;ndez P, et al. MRI findings in spinal subdural and epidural hematomas. Eur J Radiol 2007; 64:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/102\">",
"      Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/103\">",
"      Lawton MT, Porter RW, Heiserman JE, et al. Surgical management of spinal epidural hematoma: relationship between surgical timing and neurological outcome. J Neurosurg 1995; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/104\">",
"      Hemmer B, Glocker FX, Schumacher M, et al. Subacute combined degeneration: clinical, electrophysiological, and magnetic resonance imaging findings. J Neurol Neurosurg Psychiatry 1998; 65:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/105\">",
"      Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988; 318:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/106\">",
"      Vasconcelos OM, Poehm EH, McCarter RJ, et al. Potential outcome factors in subacute combined degeneration: review of observational studies. J Gen Intern Med 2006; 21:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/107\">",
"      Diamond AL, Diamond R, Freedman SM, Thomas FP. \"Whippets\"-induced cobalamin deficiency manifesting as cervical myelopathy. J Neuroimaging 2004; 14:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/108\">",
"      Doran M, Rassam SS, Jones LM, Underhill S. Toxicity after intermittent inhalation of nitrous oxide for analgesia. BMJ 2004; 328:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/109\">",
"      Ng J, Frith R. Nanging. Lancet 2002; 360:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/110\">",
"      Kumar N, Gross JB Jr, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 2004; 63:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/111\">",
"      Nations SP, Boyer PJ, Love LA, et al. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. Neurology 2008; 71:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/112\">",
"      Goodman BP, Bosch EP, Ross MA, et al. Clinical and electrodiagnostic findings in copper deficiency myeloneuropathy. J Neurol Neurosurg Psychiatry 2009; 80:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/113\">",
"      Goldwein JW. Radiation myelopathy: a review. Med Pediatr Oncol 1987; 15:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/114\">",
"      Schultheiss TE, Stephens LC. Invited review: permanent radiation myelopathy. Br J Radiol 1992; 65:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/115\">",
"      Okada S, Okeda R. Pathology of radiation myelopathy. Neuropathology 2001; 21:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/116\">",
"      Schultheiss TE, Stephens LC. The pathogenesis of radiation myelopathy: widening the circle. Int J Radiat Oncol Biol Phys 1992; 23:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/117\">",
"      Ang KK, Stephens LC. Prevention and management of radiation myelopathy. Oncology (Williston Park) 1994; 8:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/118\">",
"      ten Duis HJ, Klasen HJ, Reenalda PE. Keraunoparalysis, a 'specific' lightning injury. Burns Incl Therm Inj 1985; 12:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/119\">",
"      Cherington M. Neurologic manifestations of lightning strikes. Neurology 2003; 60:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/120\">",
"      Breugem CC, Van Hertum W, Groenevelt F. High voltage electrical injury leading to a delayed onset tetraplegia, with recovery. Ann N Y Acad Sci 1999; 888:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/121\">",
"      Kalita J, Jose M, Misra UK. Myelopathy and amnesia following accidental electrical injury. Spinal Cord 2002; 40:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/122\">",
"      Ko SH, Chun W, Kim HC. Delayed spinal cord injury following electrical burns: a 7-year experience. Burns 2004; 30:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/123\">",
"      Lammertse DP. Neurorehabilitation of spinal cord injuries following lightning and electrical trauma. NeuroRehabilitation 2005; 20:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/124\">",
"      Utku U, Asil T, Balci K, et al. Hepatic myelopathy with spastic paraparesis. Clin Neurol Neurosurg 2005; 107:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/125\">",
"      Campellone JV, Lacomis D, Giuliani MJ, Kroboth FJ. Hepatic myelopathy. Case report with review of the literature. Clin Neurol Neurosurg 1996; 98:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/126\">",
"      Sobukawa E, Sakimura K, Hoshino S, et al. Hepatic myelopathy: an unusual neurological complication of advanced hepatic disease. Intern Med 1994; 33:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/127\">",
"      Conn HO, R&ouml;ssle M, Levy L, Glocker FX. Portosystemic myelopathy: spastic paraparesis after portosystemic shunting. Scand J Gastroenterol 2006; 41:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/128\">",
"      Nardone R, Buratti T, Oliviero A, et al. Corticospinal involvement in patients with a portosystemic shunt due to liver cirrhosis: a MEP study. J Neurol 2006; 253:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/129\">",
"      Barratt DM, Van Meter K. Decompression sickness in Miskito Indian lobster divers: review of 229 cases. Aviat Space Environ Med 2004; 75:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/130\">",
"      Aharon-Peretz J, Adir Y, Gordon CR, et al. Spinal cord decompression sickness in sport diving. Arch Neurol 1993; 50:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/131\">",
"      Mastaglia FL, McCallum RI, Walder DN. Myelopathy associated with decompression sickness: a report of six cases. Clin Exp Neurol 1983; 19:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/132\">",
"      McCormac J, Mirvis SE, Cotta-Cumba C, Shanmuganathan K. Spinal myelopathy resulting from decompression sickness: MR findings in a case and review of the literature. Emerg Radiol 2002; 9:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/133\">",
"      Tournebise H, Boucand MH, Landi J, Theobald X. Paraplegia and decompression sickness. Paraplegia 1995; 33:636.",
"     </a>",
"    </li>",
"    <li>",
"     Tshala-Katumbay, D, Spencer, PS. Toxic disorders of the upper motor neuron system. In: Motor Neuron Diseases, Eisen, A, Shaw, PM, (Eds), Elsevier BV, Edinborough 2006. In Press.",
"    </li>",
"    <li>",
"     Eeg-Olofsson, KE, Tshala-Katumbay, D. Konzo. Clinical Neurophysiology of Motor Neuron Diseases. In: Handbook of Clinical Neurophysiology, Elsevier BV, Amsterdam 2005. p.675.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/136\">",
"      Ludolph AC, Hugon J, Dwivedi MP, et al. Studies on the aetiology and pathogenesis of motor neuron diseases. 1. Lathyrism: clinical findings in established cases. Brain 1987; 110 ( Pt 1):149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/137\">",
"      Tshala-Katumbay D, Edebol Eeg-Olofsson K, Kazadi-Kayembe T, et al. Abnormalities of somatosensory evoked potentials in konzo--an upper motor neuron disorder. Clin Neurophysiol 2002; 113:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/138\">",
"      Tshala-Katumbay D, Eeg-Olofsson KE, Kazadi-Kayembe T, et al. Analysis of motor pathway involvement in konzo using transcranial electrical and magnetic stimulation. Muscle Nerve 2002; 25:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/139\">",
"      Helweg-Larsen S, S&oslash;rensen PS. Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. Eur J Cancer 1994; 30A:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/140\">",
"      Helweg-Larsen S, S&oslash;rensen PS, Kreiner S. Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. Int J Radiat Oncol Biol Phys 2000; 46:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/141\">",
"      Shrivastava RK, Epstein FJ, Perin NI, et al. Intramedullary spinal cord tumors in patients older than 50 years of age: management and outcome analysis. J Neurosurg Spine 2005; 2:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/142\">",
"      Graber, JJ. Arch Neurol 2010; 67:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/143\">",
"      Sevick RJ, Wallace CJ. MR imaging of neoplasms of the lumbar spine. Magn Reson Imaging Clin N Am 1999; 7:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/144\">",
"      Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 Suppl 1:S6.",
"     </a>",
"    </li>",
"    <li>",
"     Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. In: Contemporary Neurology Series, 49, F.A. Davis Company, Philadelphia 1998.",
"    </li>",
"    <li>",
"     Eisen, A. Primary lateral slcerosis. In: Handbook of Clinical Neurology, Vol 82 (3rd series), Eisen, A, Shaw, PM, (Eds), Elsevier BV, Edinborough 2007. p.315.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/147\">",
"      Zhai P, Pagan F, Statland J, et al. Primary lateral sclerosis: A heterogeneous disorder composed of different subtypes? Neurology 2003; 60:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/148\">",
"      Andersen PM, Nilsson P, Ker&auml;nen ML, et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain 1997; 120 ( Pt 10):1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/149\">",
"      Andersen PM, Forsgren L, Binzer M, et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996; 119 ( Pt 4):1153.",
"     </a>",
"    </li>",
"    <li>",
"     Eisen, A, Krieger, C. Amyotrophic Lateral Sclerosis A Synthesis of Research and Clinical Practice. Cambridge University Press, United Kingdom 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/151\">",
"      Weber M, Eisen A, Stewart HG, Andersen PM. Preserved slow conducting corticomotoneuronal projections in amyotrophic lateral sclerosis with autosomal recessive D90A CuZn-superoxide dismutase mutation. Brain 2000; 123 ( Pt 7):1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/152\">",
"      Salinas S, Proukakis C, Crosby A, Warner TT. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol 2008; 7:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/153\">",
"      Fink JK. Hereditary spastic paraplegia. Neurol Clin 2002; 20:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/154\">",
"      Fink JK. Hereditary spastic paraplegia. Curr Neurol Neurosci Rep 2006; 6:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/155\">",
"      Gould RM, Brady ST. Neuropathology: many paths lead to hereditary spastic paraplegia. Curr Biol 2004; 14:R903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/156\">",
"      McDermott CJ, Shaw PJ. Hereditary spastic paraplegia. Int Rev Neurobiol 2002; 53:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/157\">",
"      Reid E. Many pathways lead to hereditary spastic paraplegia. Lancet Neurol 2003; 2:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/158\">",
"      Boukhris A, Stevanin G, Feki I, et al. Hereditary spastic paraplegia with mental impairment and thin corpus callosum in Tunisia: SPG11, SPG15, and further genetic heterogeneity. Arch Neurol 2008; 65:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/159\">",
"      Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol 2007; 3:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/160\">",
"      Griffin JW, Goren E, Schaumburg H, et al. Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. I. Clinical and endocrinologic aspects. Neurology 1977; 27:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/161\">",
"      D&uuml;rr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996; 335:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/162\">",
"      Bhidayasiri R, Perlman SL, Pulst SM, Geschwind DH. Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. Arch Neurol 2005; 62:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/163\">",
"      Milhorat TH. Classification of syringomyelia. Neurosurg Focus 2000; 8:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/164\">",
"      Brickell KL, Anderson NE, Charleston AJ, et al. Ethnic differences in syringomyelia in New Zealand. J Neurol Neurosurg Psychiatry 2006; 77:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/165\">",
"      Larner AJ, Muqit MM, Glickman S. Concurrent syrinx and inflammatory central nervous system disease detected by magnetic resonance imaging: an illustrative case and review of the literature. Medicine (Baltimore) 2002; 81:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/166\">",
"      Laxton AW, Perrin RG. Cordectomy for the treatment of posttraumatic syringomyelia. Report of four cases and review of the literature. J Neurosurg Spine 2006; 4:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/167\">",
"      Batzdorf U. Primary spinal syringomyelia: a personal perspective. Neurosurg Focus 2000; 8:E7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/168\">",
"      Todor DR, Mu HT, Milhorat TH. Pain and syringomyelia: a review. Neurosurg Focus 2000; 8:E11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/169\">",
"      McCormick WE, Steinmetz MP, Benzel EC. Cervical spondylotic myelopathy: make the difficult diagnosis, then refer for surgery. Cleve Clin J Med 2003; 70:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/42/32426/abstract/170\">",
"      Baron EM, Young WF. Cervical spondylotic myelopathy: a brief review of its pathophysiology, clinical course, and diagnosis. Neurosurgery 2007; 60:S35.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5093 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32426=[""].join("\n");
var outline_f31_42_32426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFLAMMATORY DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transverse myelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Paraneoplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute viral myelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AIDS myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HTLV-1 myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Parasite infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      VASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Spinal cord infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Vascular malformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Spinal epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TOXIC, METABOLIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Subacute combined degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20816123\">",
"      Copper deficiency myeloneuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Radiation myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Electrical injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hepatic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Decompression sickness myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Lathyrism and konzo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INHERITED AND DEGENERATIVE CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Hereditary spastic paraplegias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Friedreich ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      OTHERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Syringomyelia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Cervical spondylotic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5093|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/9/12439\" title=\"diagnostic image 1\">",
"      MRI Transverse myelitis and MS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5093|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/0/6157\" title=\"table 1\">",
"      Spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/47/34557\" title=\"table 2\">",
"      Evaluation of transverse myelitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28713?source=related_link\">",
"      Central nervous system tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27944?source=related_link\">",
"      Cervical spondylotic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26697?source=related_link\">",
"      Chiari malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/47/22264?source=related_link\">",
"      Clinical manifestations and diagnosis of West Nile virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7190?source=related_link\">",
"      Complications of spinal cord irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11880?source=related_link\">",
"      Copper deficiency myeloneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4410?source=related_link\">",
"      Environmental electrical injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18842?source=related_link\">",
"      Evaluation of neck stiffness in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16138?source=related_link\">",
"      Familial amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15432?source=related_link\">",
"      Friedreich ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40808?source=related_link\">",
"      Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5897?source=related_link\">",
"      Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33753?source=related_link\">",
"      Inhalant abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=related_link\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6583?source=related_link\">",
"      Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/57/3986?source=related_link\">",
"      Patient information: Friedreich ataxia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/53/27475?source=related_link\">",
"      Patient information: Paraplegia and quadriplegia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/9/13465?source=related_link\">",
"      Pelizaeus-Merzbacher disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/49/37656?source=related_link\">",
"      Skeletal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23333?source=related_link\">",
"      Spinal cord infarction: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40631?source=related_link\">",
"      Spinal cord infarction: Vascular anatomy and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/63/7161?source=related_link\">",
"      Spinal cord tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14807?source=related_link\">",
"      Treatment and prevention of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12408?source=related_link\">",
"      Unusual causes of adrenal insufficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_42_32427="Urine Cl in metabolic alkalosis";
var content_f31_42_32427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Urine chloride concentration in the diagnosis of metabolic alkalosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Less than 25 meq/L",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vomiting or nasogastric suction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diuretics (late)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Factitious diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Posthypercapnia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cystic fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Low chloride intake",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Greater than 40 meq/L",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary mineralocorticoid excess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diuretics (early)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alkali load (bicarbonate or other organic anion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bartter's or Gitelman's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Severe hypokalemia (plasma [K+] &lt; 2.0 meq/L)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32427=[""].join("\n");
var outline_f31_42_32427=null;
var title_f31_42_32428="Cancer screening in transplant";
var content_f31_42_32428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested guidelines for cancer screening in patients undergoing solid organ transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cancer type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast",
"       </td>",
"       <td>",
"        Women 50 to 69: annual screening mammography with or without clinical breast examination; age 40 to 49: the benefit of screening is less certain, and should be left to the decision of the physician and patient; &ge;70 years of age: annual screening is appropriate as long as estimated life exectancy is &ge;8 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        Monthly self examination; physician examination annually, with early referral for suspected lesions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical",
"       </td>",
"       <td>",
"        All women &ge;18 years old and sexually active girls &lt;18 years old should undergo an annual pelvic examination and PAP smear.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anogenital",
"       </td>",
"       <td>",
"        Yearly physical examination of the anogenital area, including pelvic examination and cytologic studies for women. Insufficient evidence to recommend for or against screening anoscopy and biopsies of anal epithelium.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KS/other sarcomas",
"       </td>",
"       <td>",
"        Examination of skin, conjunctivae, and oropharyngeal mucosa annually; patients at higher risk (ethnicity, geographic area of residence or serologic positivity for HHV) may benefit from more frequent screening.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostate",
"       </td>",
"       <td>",
"        Annual screening with digital rectal examination and PSA recommended for men &ge;age 50, if their estimated life expectancy is at least 10 years. If positive family history or African American race, may start annual screening earlier (eg, age 45).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colorectal",
"       </td>",
"       <td>",
"        Starting at age 50: annual FOBT and either sigmoidoscopy every five years or colonoscopy every 10 years*.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PTLD",
"       </td>",
"       <td>",
"        Complete history and physical examination every three months, particularly in the first posttransplant year; patients at increased risk of PTLND may benefit from more frequent screening.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung",
"       </td>",
"       <td>",
"        Not recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HCC",
"       </td>",
"       <td>",
"        For patients with chronic hepatitis B or C and cirrhosis, serum AFP and liver ultrasound every 6 to 12 months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal cell",
"       </td>",
"       <td>",
"        Screening via cytologic or radiographic means is not recommended, except possibly for patients with a history of analgesic abuse.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     KS: Kaposi's sarcoma; PSA: prostate specific antigen; HHV-8: human herpesvirus 8; FOBT: fecal occult blood testing; PTLD: posttransplant lymphoproliferative disorder; HCC: hepatocellular cancer.",
"     <br>",
"      * At some institutions, screening is started at age 40 or five years after transplant, whichever comes first.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Kasiske BL, et al. J Am Soc Nephrol 2000; 11:S1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32428=[""].join("\n");
var outline_f31_42_32428=null;
var title_f31_42_32429="Self measurement of INR";
var content_f31_42_32429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Correlation between self-measured INR and laboratory INR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 389px; background-image: url(data:image/gif;base64,R0lGODlh4wGFAdUAAP///wAAAICAgCAgILCwsE9PT7+/v8DAwEBAQM/PzxBA//Dz/9DZ/zBZ/2BgYBAQEHBwcDAwMKCgoNDQ0ODg4PDw8LDA/1Bz/8DN/1BQUCBN/4CZ/5Cm/3CN/+Dm/0Bm/6Cz/2CA/5CQkB8fHwAz/z8/Pw8PD6+vrxATIAAjrzBJryA8r6CjsAAGH4+Pj5CWr4CJr5+fn3B8r1BjrwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADjAYUBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DRnhUH1dUV0tnaYwcB3t4H2+LjWtQHEt4U5OvsVA4BDu3y80sU6UUHAvr7/Pvh9ACbvYuHr59BAQgEBFyYrFsAdVL0MZxYDEEACFQkUtw4TiPHj9I8ghzZTCTJk8hMolw5TCXLl75cwpyZSybNm7Rs4tz5SifP/5+qfAIdWkoo0aOgjCJdukkpU1UEBngbQGCj06enCAQoYMBAgQBVJ17FWmpAASIFBlAcS3ZUgAREDARYq7CtrAAGiCSYK7auXVhm0art+zeW1gIJvIKlW9iw1ABUrfptTDkS28qY/VzOzDnP5s6g6XwOTfrN6NK2LFhoORm1sQ4KVgs77RqWhwYNPBCjXbsVCAUdjPHunWpBCAUYjg0nbopBgw8LUrZmnuv3BmXLqYNacAH5suzaOzHQcCH69+nhY3EgwcEZ+KNRp4Z1xV0Dg2fvhx7u+nX+qvHlQZMfUIENkVYrGyjQXjQD/vRWXHwV90ED94WEXml46RXhKRgoEP+CeRZSV6AQB6KSIAjiNMjTYYn1R0p8AaCwQoXbqLjiY5GNsp9i/mVjY3qFjAhAicjkcxA/CQF5yoNDyKWMkUfqk6SSpFiQ4RB7dXQhlZoYp4CQRGrzI5d8OAcdizxqSaYn1g0BY44pbrmmJF4mt9CYc9JhJogB4ZlnHOtdx9ifk9RHI2GERgIgn4iW9maPmKy34Ed+krSji5ks8IF9JFU6EpiDXdLhhyd5ChKTQjh5yYkrmfrRlUJkWYmmFLLkKkegVmKBh4x2KidlaGIqCWyyvXQrR49OcltuNB2bKBa7BneTs89WQexO1FYbhXPMYvurtnO0+VO24C5R51Dklov/xJ5EpatuERwoIGi7376LRn12HuXuu4sytW+5kmL1b7WGkjVwohiQ1ytSB//Jql0Nr0nroQbXa28Xoy78VMRUPtwYx8S9yQJuFP8Fcm2XBjADZye7lmtmLaOGKgCqYhYzhnlhuSFlN4e2AApnGRhqZT135pwKW7W4GMwWX/xEm8m2g40bRVd27jzUTE1ABqY17bQS/c5DwQMBPHAABAEggIU11UTk9ddHBAyQCGmTXbYEWHzjjdtwU1Fwn2prFQFEV4DTdhRVtxV2nwMI8I4+eBeedgb/DAFllFP2/cQG7K2ltzdqX5GB42UTDsDlR2auubkTlkxE1NmgLkDkWVhU/7kTiS+VsRIpQ7rSARGQ/sDUT+R+lMdJvCyN7LRTQUEE3kQwAd+rI+FB603MXDODn6fddfVHRKuxEbACIKs0FFQjgVQPiPA9+ERc+4Ty2YhAtgOms2E8TsvqBkWwS5PGBKAXgdtR7W3sgB0hokUFBXIvbQiIIEYOaKnu+a4PC5CfrboXujbsjxSP0dvQ/mAm/z3rg27p3s76IK6ZSGCCQnjh+06lQkBcrVmN20cEZ/iREH5jhHpgF04EwEEeIsuCfgjUuHIopQ7qD4HreMc3CLKHv/FEhkPAogehOA6tfO6Cc1icvVAoCh9ORQ9y+xoZQ6HCFcpBU5zq2xpB0cY77P9Oc3P8hBkhYwfk6csgzVtDHj3hRb2BcQ0Tw4oKnShILnYRR4dUwx2fUo0BiKAaqmskoWCDor8sDSFGpFL/GjOABwgAAg/gGgXXxEDKTMBuD5jeKrmkwcocLpTa4ZYJKVMBCCBgAhmIJBkGCY0WYiYD4HCAKrcIpBtmJgAiQEA+GKkGYjJDiJ0BizQRsMwnhseYnXHAAx4glUBW05FtwRdqKoDMB8CQmcQRY2gkYE541iaNqMkANe1ZGituwYEoWZ81ZMnP0CQsQF0o5DeESRGLfGOfaLCmMBI0qS7sEYgkkQA/6hlRdA4lkWCoI6EkygqAGmGSXxApSxwKOlzipHf/SvDjFy4KE19G8CIuvQn9iLAs13lBod5g6EeCl1OaaM+NrTSDSVdSgQFA9Awk5cJS7aDA8p1vCLVUEkvhUVRRwHQPQA0g/Zb1AkgqyaYIcADxvLmKnd6BpkIA4HyiFVahlmYC+dPkKo7KB5UCIGrngmt40upFgn5BdgbJ5JJyFis31sGvRxAiZJmjzQFEgIqHjZIOPVoJt15hqlAQbFxxJAN5EWGyxAnAAR7gAFDOMhVylSoSPzvbuHYPBkUQLXUiIBUROOCpZojqP83KBd02kLhD0G1dgbTawbWvq8VAbRcmC1r4QUG4fZAuF7RLJgnYzXuvZYZxu8CAFnQPo3Ma/4BUEMBa6BJjuWHYQApUaNfwgGUuEMCsXp9RXSvQqgUFOMEIfggu1QZPn+4lScb4qq3LEhGn4Z3Jw6zqWEKJwH0J5ghIAeDZJfS3MQQQAAUEYNj9wkR8r9vKgL3xzibANzRoU20G9HtOmmRVCDE2ZGjPWxrWFtC1BT3JKI8w3iRwtzGqleZvM+yM/ib1CEcuQpT/ggDeIhPDQRbHi42QwdgsYcrJ5TFpXhm9tZqYHEUuIROKjIQth+YAJWYrO1ALziS4mQkf/ksFRLAPjkKVs8SArDPxjNxn+RC4ZcAuIkTrnBSgQD5/LTTcAkC5asQ5DYo+xIvXgzSuKOYdnhbWcP8hTZr8ziHTmiauocC0FcEkdCv8CWBn0PFQJmujX0eFS5MqTIUOU6ZsEURAi2v8XklPIY0UZqz5eD0FBoOmcacGNCgc+NUp+JPVQSMRet1kbPIp+6qcgQAT/RxcaRMS1mlKbraHtO0ldAihbkrap+UtaiPcObfrDhNntoroYZq7E/RzNhRkOlpIV5fNtkVMukEzAbZduqO4EDiFo7DhPCshyhYHH6rDMHF1u/oJk7w3FMBMnG7IYeNgoB8AHdBtrCqgk2H+XLubgPDwmDwOKP9CbF+HIynq2AhDPm0NrSBy5jL7z7k4uJiJ8GShdw8LGUfNAbAxgX6XWxmQvXHMRRj/hahTR7UQIDem/92J6qpUl7yrrYvRXe88UdqpfbZ1VtRuBLjW+Qg+52po8z3zsxYxwrJAeF0H3Wa6f1nXqTq6kgbogIHK3RRHfhPLSb2Emkv524q3bhZy7gWSV9vIQ3eCr7kU7NIPe+wlNbblhbCA0QuB5H9V8TdOv6ZFPh4Tn4/9F5swHoEjYY+QoXwScrxQzfu7rXy3d8vhxZ6Op717oZY1kZeeqF7+Mpi3v4Tvj+DAgrm+4MFP/sVDnyhkqlaZ2beE8wv/OXFPZQUI3fnIEU8zZsNeO9CUJpDljArXAz/686EVJuANA+g7DrR+0ydz2qJNB8BNWDABfCYBZtYE/5z3P/QmfeRDfkTiVp/nekVHJuJETgEgdtlTa4hDdo9gUm/iVzWzfSp3gcLkddTBTmVDe1GAN/aQeURQgbIVfd0zAhoyBAgIAL4ng+qSPltwNgHQGojVD4oVePkGfR/HYQG2YpDxKENofEVAN3BGNhEwgVMgARbRYk2IJCioCUclQgEwgGsYQGHVRuKnhUiQAVzzDtCDZVhgOycYccp2AmxHX0QAfCqkcG0nh0OQJFJhfVcAPKd0D9d1hpkgJCOwbmzIdULYRl+0fIZIh/YQAQCwf1PwPMKHO5CIe23YhvSHiVeoinpjiE9Aa0sIAJeVfpDQX2EVA073ObHGimfkiv9O8A4IQA0jSIuOkHt194NEUInfAIQkwosY6IuaUYqE4HpwqDTdcwK79ihGCI1wwINIUIQ4wgJtBEkwEgAuEITc6AjeCGWYl2K8OELlWIVqeIXpmAjrWHdxyGHO6B9v+DklEGv1xW2jWI+o9yIwmIuGJGmCqDfMyG5SYIwEeXWlcIDkB2XOuGtS8H0R+QX7s40ehiMqNHPOGCHglj30tz0bKZGDAJFFAFDayIuRtJDLKDRSkIUpKQbG44F/yI9/+F3zCCd2xosloDQBSYVTeJOJJo1jsH34dpSsVpEuFkLy+EMDuXaE+IxICQbGY5NCeJIbkoZPVwVM+ZCamJVdkJP/+ciOGgKSmIeJkfEmAmBsXGmWfGA88vd7URh9+eaTKgRqXVECdKeRdHkHHVmWsXeVeUmU5TiIQ2CFBLaDF6iUg6mVklkHK+iVj0aPCPkNiAdZA1ACKzYCJdB3k2kH3khhXmaR3cNYkDWWpekZlTkHj2IWAvZDu5RbjCkEjtmLQtiOr/kHqJYyeVd87Kc3oJYYgLl7gRiFhvmbgAcJoCJ4ZgWXxgZAOykHHimHqAaWYRkGK5iWbPCBKbmdbQmVYuCaaLB6BIlqYIIC6qkFc3kG9weNwQmD4mlR4LkG8+mLGxc12fmQBwkH75mOG+dPcPCfWnCfEdkzUfdufJIsCEoI/xFqXTejoELgR8J5nc4ZCjezehvmcQbSajS5oUkRm1kQZSjVlRDilSRaon9wZJxkZJjnmy3aCR1KfUUQdESWl2gRfJpZo5dQoYYnBE13BER0ldBzlRoKpJXAoC2ndXUHmt4gmlQBkvnJpI+QRzp6cSx6Wl2KpZMwR78hLU6AgPEJpvZoomJAeJWXloKJpoWAQtj0BHd5mEQJp5LwQXfnBCrYnHgap2raBdzhHX9aE4G6BfJEaFVZqI9Qhps1CPjEp0vKqJHgqFJyqFdgoKJ3pZSKCT1zUONzeBDSqZ9wMxRlBWdKqnmKqVLwoVPwpqqqjqwKBSk6BXUaq0E6q05AcP/Htai4SgkRcz218qu80DAoRqzFqqtJAKVjMKHIenLKCnS4cZtKNanPegj7UqRnAKvXqgfp4iXFop9f2q2GQC6NlplAKZ80Sq6ACge/0WkAqQbcyq6mqat1Mq9QF6D0SgjHwi7o6Z1+uq94cCvItq4CKwumcm3M6asHewqeIk/WCYAN6wqVEqkCGX5HObGpgCdw5FPkM64aiwpjUqs8NxWpGrKe8CO8Gm96mbEoWxTS6Ko72qNXWZQvm6thsCukwgRHFbA3qwkDwqzeho4/uwrvsaXKZ7KcWrSjAB7a2pJ/qK9MK7L/JrQg2ow+O7VNIW1qZpKjqrUUC2h7+o0GC7b/G+tRbKoE+Gq2QItOcyqpNcu2rPAZ8TIvZMmwcisKl6FOeSscCJSofRsMY2GxgTsbTaOphWu4TuCgiSsdTbCyjQsMPiGzkcsaSkCylau4SAC5mbsKcDYFLoG0ndsKE0BEVmcEKvG0o8sKDnW6RZC64bq6sdANrruD0Sq7jEC7RmCpCHG7uKsIulsQmqUPBvS7tACBAVBAYGi8xLBVxcu80Bu90nsKvDu81nu92Ju92ru93Nu93vu94Bu+4ju+5Fu+5ju8z0sKvXu+7BtB7Hu+7vu+5hu/8lu+9Fu/4nu/+Ju/vgubddm/SHAyLSPAAKwE97gEBLwHCfy/DNwHB2zA/wVspBH8uhNMwQ5cwbYbjUaLwUMAMguswBwsBDHzwEnwwQMbwp+IwincwCxMtS1MmCg8wDGswiscFDMMwi98wjmswza8w6Jxwz78wxrcwzjsrUBcxEY8xGcbxNDKxNHmxE9MxEk8xVRcxTwMxaV6xFfsv1hMjCqJCreUB2F8B2NMxulbB2VsB2lsxtPbxm78xnAcx3I8x3Rcx0/wubUAgbOzvLDANmf8CuZgDXz8CaULXrSgN7WLCp+DCw7xDX/sCa1rCzi4N7dgOI/cCuZAa3k1CsFbC0pIw3oAOpSzCwOhCp1MC2IIYbYwOu/wAJssCzn4yqJwyrWgh7lgy7dQyv+pgLzKOwuMGGOy3AqM2MqD7AoOEcyg4LyzIIo/SgvMLD23rMp2PM3UXM3WfM3YnM3avM3c3M3e/M3gTBFrLARVR4JlkD7WAAANBxGfG8iXHM5UQMlI0A0eRUTvbMCtaBEDgA3e08ilA8/TtSFiyE1V0Q35hQBhMQG/BQHYMGIHQAB4Y1MOgFcW4QB4o9DC1tAC8NASEGLqoFFrFbwOpRD97D2PA9DbtSEZAAFx+RDd0DjQg1cPEDwzfTpl4z2Ng0oDMAFSEQEQMDY07YndQDYIgA7uQ074AF4WYRETUNJqg0zmjNJluiEjhgBSUQ2xqBUCQDdVgTYNp8pnw15zYc/sAMDVAODVBi0EFTDTWoGHNh06FmEPS23TUyTVWyDPQC0B74DVCkHPZG3P9GxbwQQ9n6hahR0OgB2LQmCHAWBmIj3WLdUNEWAR3WTXqLqExEtpDaha3dB4Md3UlFNKNl0XRCQA8VHYGw3aByDagS0EDlHZFEA3BQQAFgEAa+3Ut+3Wlt1srdjK0IPVZPMAkbM+yTs9rV0B0KNec0EBUsE1xA3NrS0EUtEjD7Y3tQ0A6KA2uqsVsbTbjVABfOTdp0A3oCze5n3e6J3e6r3e7N3e7v3e8B3f8j3f9F3f9n3f+J3f+r3f/N3f/r0NQQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The filled and open symbols represent self-measured and laboratory international normalized ratio (INR) from patients taking phenoprocoumon or acenocoumarol, respectively. The self-measured INR was determined from a capillary blood sample obtained and analyzed at home, while the laboratory-measured INR was determined from a venous blood sample assayed virtually simultaneously. The line of identity is shown in blue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000; 356:97.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32429=[""].join("\n");
var outline_f31_42_32429=null;
var title_f31_42_32430="Hyperglycemic complications";
var content_f31_42_32430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Mechanisms of hyperglycemia-induced vascular complications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow diagram showing how too much glucose may lead to the long-term complications of diabetes.",
"    <div class=\"footnotes\">",
"     AGE: advanced glycosylation endproducts; DAG: diacylglycerol; PKC: protein kinase C.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32430=[""].join("\n");
var outline_f31_42_32430=null;
var title_f31_42_32431="Injection Dupuytrens";
var content_f31_42_32431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Local injection for Dupuytren's contracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hand is placed in the palm up position. Ethyl chloride is sprayed on the skin for anesthesia. A 5/8 inch, 25-gauge needle is inserted vertically adjacent to the nodular thickening in the midline over the flexor tendon, to a depth of 1/4 to 3/8 inch. 1/2 mL lidocaine and 1/4 mL triamcinolone acetonide (40 mg/mL) are injected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_42_32431=[""].join("\n");
var outline_f31_42_32431=null;
